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 The Radiological Physics Center (RPC) uses both on-site and remote reviews to credential 
institutions for participation in clinical trials.  Anthropomorphic quality assurance (QA) phantoms are 
one tool the RPC uses to remotely audit institutions, which include thermoluminescent dosimeters 
(TLDs) and radiochromic film.  The RPC desires to switch from TLD as the absolute dosimeter in the 
phantoms, to optically stimulated luminescent dosimeters (OSLDs), but a problem lies in the angular 
dependence exhibited by the OSLD.  The purpose of this study was to characterize the angular 
dependence of OSLD and establish a correction factor if necessary, to provide accurate dosimetric 
measurements as a replacement for TLD in the QA phantoms.  A 10 cm diameter high-impact 
polystyrene spherical phantom was designed and constructed to hold an OSLD to study the angular 
response of the dosimeter under the simplest of circumstances for both coplanar and non-coplanar 
treatment deliveries.  OSLD were irradiated in the spherical phantom, and the responses of the 
dosimeter from edge-on angles were normalized to the response when irradiated with the beam 
incident normally on the surface of the dosimeter.  The average normalized response was used to 
establish an angular correction factor for 6 MV and 18 coplanar treatments, and for 6 MV non-
coplanar treatments specific to CyberKnife.  The RPC pelvic phantom dosimetry insert was modified 
to hold OSLD, in addition to the TLD, adjacent to the planes of film.  Treatment plans of increasing 
angular beam delivery were developed, three in Pinnacle v9.0 (4-field box, IMRT, and VMAT) and 
one in Accuray’s MultiPlan v3.5.3 (CyberKnife).  The plans were delivered to the pelvic phantom 
containing both TLD and OSLD in the target volume.  The pelvic phantom was also sent to two 
institutions to be irradiated as trials, one delivering IMRT, and the other a CyberKnife treatment.  For 
the IMRT deliveries and the two institution trials, the phantom also included film in the sagittal and 
coronal planes.  The doses measured from the TLD and OSLD were calculated for each irradiation, 
and the angular correction factors established from the spherical phantom irradiations were applied to 
the OSLD dose.  The ratio of the TLD dose to the angular corrected OSLD dose was calculated for 
each irradiation.  The corrected OSLD dose was found to be within 1% of the TLD measured dose for 
all irradiations, with the exception of the in-house CyberKnife deliveries.  The films were normalized 
v 
 
to both TLD measured dose and the corrected OSLD dose.  Dose profiles were obtained and gamma 
analysis was performed using a 7%/4 mm criteria, to compare the ability of the OSLD, when 
corrected for the angular dependence, to provide equivalent results to TLD.  The results of this study 
indicate that the OSLD can effectively be used as a replacement for TLD in the RPC’s 
anthropomorphic QA phantoms for coplanar treatment deliveries when a correction is applied for the 
dosimeter’s angular dependence.  
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Chapter 1 Introduction 
1.1 Statement of Problem  
 The current standard of practice for mailable anthropomorphic quality assurance (QA) 
phantoms for the purpose of remote audits by the Radiological Physics Center (RPC) includes the use 
of thermoluminescent dosimeters (TLD) as an absolute dosimeter within the phantom.  The TLD have 
been shown to be able to identify calibration errors greater than 5%, and to have an accuracy similar 
to ion chamber measurements with a high degree of precision1.  There are several downsides to using 
TLD for remote audits, however, including a long wait period following irradiation before being read, 
temperature and humidity dependence, destruction of signal after a single reading, and a long reading 
time.  The RPC has already made the switch from TLD to optically stimulated luminescence 
dosimeters (OSLD) in 2010 for remote external beam output monitoring.  The benefits of OSLD 
include lower cost, a shorter wait period following irradiation, simpler readout procedures, minimal 
energy dependence, they are reusable, can be re-read, and they are not affected by changes in 
temperature and humidity.  The use of OSLD for this purpose has been well studied and validated by 
the RPC, and under reference conditions, has been shown to agree well with both ion chamber and 
TLD measurements for both photon and electron irradiations2.  The switch from TLD to OSLD in the 
anthropomorphic QA phantoms is also desirable, for the same reasons as stated above.  However, the 
use of OSLD in the RPC’s anthropomorphic phantoms has not been studied for evaluation of special 
treatment techniques, nor for credentialing of institutions to participate in National Cancer Institute 
(NCI) sponsored clinical trials. 
 The problem with implementing the OSLD in the anthropomorphic phantoms lies in the 
angular dependence exhibited by the dosimeters.  Kerns et al.3 demonstrated a decreased response of 
the nanoDot OSL dosimeter of 4% and 3% for 6 MV and 18 MV beams incident parallel to the plane 
of the dosimeter, respectively.  For a radiation treatment with multiple fields at different gantry 
angles, some or all of the beams could be oriented such that the OSLD demonstrate the decreased 
angular response.  The magnitude of the angular response could potentially be important and should 
be accounted for in the calculation of dose.  This observed under-response of the OSLD was 
attributed to the non-uniform geometry of the nanoDot dosimeter.  A lower fluence of the primary 
beam is incident on the disk shaped sensitive volume of the dosimeter from an edge-on orientation, 
which causes the majority of the dose at that orientation to be from scattered photons and low energy 
Compton electrons.  The stopping power ratio of the sensitive material relative to water decreases 
 with decreasing electron energy, so as compared to the dose deposited in a face
higher energy electrons, the dose deposited by the lower energy electrons would be less.
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treatments.  The RPC monitors the radiation therapy programs of each institution by on
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Figure 1.1 Anthropomorphic QA phantoms: prostate (upper left), thorax (upper right), IMRT head 
and neck (lower left), SBRT spine (upper middle), SRS head (lower middle), and SBRT liver (lower 
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1.3 Optically Stimulated Luminescence
1.3.1 OSL Phenomenon 
 The phenomenon behind optically stimulated luminescence (OSL) is the same as that behind 
the TL process, with the stimulation method being exposure to light, rather than the application of 
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heat.  The model consists of two energy levels, the valence and conduction bands, which are 
separated by a forbidden region.  Defects purposefully introduced into the crystalline structure of the 
material establish local energy levels within the forbidden region, which are called traps.  Exposure to 
ionizing radiation excites the electrons to the conduction band and the holes left behind move to the 
valence band, creating electron-hole pairs.  The electrons that have been excited to the conduction 
band and the holes in the valence band can move freely within the crystal lattice.  The electrons will 
stay in the conduction band until they move back to the valence band and recombine with a hole, or 
are captured by an energy trap in the forbidden region5.  The electrons that have been captured by 
energy traps cannot recombine with a hole without first being stimulated.  Exposing the material to 
light stimulates the trapped electrons back to the conduction band, from where they can recombine 
with holes.  This recombination of an electron-hole pair creates an excited state of the recombination 
center, and results in luminescence.  A process of hole capture can occur, where a hole in the valence 
band can combine with an F-center to create additional recombination sites6.  
 Depending on the energy level of the trap within the forbidden region, the trap can be either a 
dosimetric, shallow, or a deep trap.  The dosimetric traps are deep enough to keep charge from 
spontaneously escaping at room temperature, but they are shallow enough that the charge contained 
can escape by exposing the material to visible light.  These dosimetric traps are responsible for the 
luminescence measured in OSL dosimetry.  Ideally, the amount of charge captured within the 
dosimetric traps is proportional to the absorbed dose of the crystal.  Traps that are close in energy to 
either the conduction band or the valence band are called shallow electron traps and shallow hole 
traps, respectively.  Deep electron traps and deep hole traps also exist within the forbidden region, 
further in energy from the conduction band for the electron traps, and further from the valence band 
for hole traps.  Yukihara and McKeever5 describe the influence of charge capture by both the shallow 
and deep traps on the OSL signal.  Shallow traps are associated with phosphorescence directly 
following irradiation, as well as after exposure to light.  Directly following irradiation, charges from 
shallow traps escape and recombine, releasing luminescence.  Phosphorescence after optical 
stimulation occurs when charges from dosimetric traps escape, but then are captured by shallow traps.  
Another important process associated with shallow traps is the initial increase in signal intensity when 
the material is exposed to light.  At the beginning of the stimulation, a large number of shallow traps 
are available and can trap charge coming from the dosimetric traps, but as stimulation continues, 
these shallow traps become filled and more of the charges escaping from dosimetric traps will 
recombine and release light.  Deep electron and deep hole traps affect the sensitivity of the material 
by competing with the recombination process, both during irradiation as well as stimulation.  The 
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deep traps may capture charge that has escaped the dosimetric traps, but as the deep traps fill, more 
electrons recombine and contribute to the OSL signal.  This process causes the dosimeter to have a 
dependence on the history of irradiation, due to a residual signal from previous irradiations that can 
be difficult to remove from the crystal. 
       The shape of the luminescence curve versus time can be modeled by an exponential decay, if 
stimulated by a continuous exposure to light of the appropriate wavelength.  The concentration of the 
shallow and deep traps will affect the OSL curve, but the simplest approach is to assume that the 
electrons do not fall into another trap after escaping the dosimetric trap, and they are allowed to 
recombine.  The light resulting from the recombination of the electron-hole pair is collected to create 
the luminescence curve, and the integral of this curve is proportional to the total absorbed dose of the 
material. 
1.3.2 Properties of Al2O3:C Dosimeters 
 The material most commonly used in commercial optically stimulated luminescence 
dosimeters is carbon-doped aluminum oxide (Al2O3:C).  This material was originally investigated as a 
material for thermoluminescence (TL) dosimetry, with approximately 60 times higher TL sensitivity 
than LiF:Mg,Ti7, but when it was shown that the TL signal was susceptible to light exposure, the 
material was implemented as an optically stimulated luminescence dosimeter.  A low effective atomic 
number is a desirable characteristic in a material used for dosimetry; however, the higher effective 
atomic number of aluminum oxide, 11.288, leads to an increase in energy dependence of the 
dosimeter, especially at lower energies, that must be accounted for if used to be an accurate radiation 
dosimeter.    
 Al2O3:C can be produced as single crystals, or as powders of varying grain sizes.  The 
crystals are grown in an atmosphere that prevents oxidation keeping the presence of oxygen low, and 
introducing carbon.  This atmosphere creates a high concentration of stable oxygen vacancies and 
defects in the crystal lattice.  When the oxygen vacancy is filled by two electrons, a neutral F-center is 
created.  If the oxygen vacancy is filled with a single electron, a positively charged F+-center is 
created.  These F and F+ centers contribute greatly to the luminescence sensitivity of the material, and 
are present in aluminum oxide in concentrations of 1017 cm-3 and 1015-1016 cm-3, respectively9.  
Electrons that have escaped traps recombine with the F+-centers, creating excited F-centers, which 
then relax back to the ground state by emitting luminescence5,9.  F-center emission is centered at 420 
nm with a lifetime of 35 ms at room temperature, and F+-centers produce luminescence at 330 nm 
with a much shorter lifetime of less than 7 ns10. 
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 An advantage of carbon-doped aluminum oxide is the wide energy forbidden region, 9.5 
eV10, which allows the local energy levels in the band gap to be distant enough from the conduction 
band to be thermally stable.  If the gap between the valence and conduction bands is too narrow, the 
traps are too shallow to hold charge at room temperature for any length of time.  Another advantage 
of the material is its uniformity in sensitivity and properties, due to having a homogeneous mixture of 
different crystal sizes5.  The main disadvantage of the material is the residual charge that is stored in 
the deep traps, which need more than optical bleaching to be removed.  According to Reft11, for 
absorbed doses up to 2 Gy, optical bleaching will remove virtually all the signal without changing the 
sensitivity of the material, but for doses above 2 Gy, annealing with fluorescent lights does not 
remove all trapped charges.  However, annealing with a tungsten-halogen lamp (THL) for 3 minutes 
will remove the signal.  It has also been shown that annealing the dosimeters with high temperatures 
will empty the traps of all charges12, but dosimeters enclosed in plastic cannot withstand the high 
temperatures necessary. 
 The response and measured signal is dependent on characteristics of the material and the 
reader system, such as energy dependence, fading, linearity, and depletion.  The Al2O3:C dosimeter 
characteristics have been previously studied, and will be briefly outlined here.  The energy 
dependence of the OSLD was investigated in Viamonte et al.13, and it was shown that when 
dosimeters are calibrated using a 60Co beam there is a 4% decrease in the sensitivity for higher 
energies, making it necessary to apply a correction factor.  The response of the OSLD has been shown 
to have no dependence on dose rate13,14.  Jursinic15 investigated the changes in the dosimetric 
characteristics of the OSLD with accumulated dose, finding that dosimeters with greater accumulated 
dose experience a greater degree of supra-linearity.  He suggested that dosimeters that are to be used 
multiple times, repeating the cycle of annealing, irradiating and reading, could make measurements 
with high precision if the individual OSLD are characterized after each annealing to account for 
changes with accumulated dose.  Aguirre et al.16 have reported that the characteristics of individual 
dosimeters need not be investigated after each annealing, and is independent of the number of cycles 
it has been irradiated and annealed, provided the accumulated dose to the dosimeter is less than 10 
Gy.  It has been shown that up to an accumulated dose of 20 Gy, the sensitivity of the OSLD remains 
the same, but above 20 Gy the sensitivity decreases by approximately 4% with every 10 Gy additional 
accumulated dose11,17.  The linearity of the OSL response for an irradiation has been studied 
extensively, and it has been shown that the response of the dosimeter is linear up to a delivered dose 
of approximately 2 - 4 Gy11,13,14,17,18, with supra-linearity observed at higher doses.  An explanation 
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for the observed supra-linearity was given by Jursinic17, attributing the response to the competition of 
the deep traps described in Section 1.3.1.   
 An initial rapid decay of the signal that has been observed in OSLD, called the transient 
signal, is due to spontaneously escaping charges from the shallow traps without optical stimulation.  
The decay of the transient response affects the initial intensity of the signal, but does not greatly 
affect the total area under the luminescence versus time curve19.  Several studies have shown that 
after 8 minutes, the transient signal has decayed and the signal is stable11,17,20.  Perks et al.20 reported a 
2% decay in the signal from 10 minutes to 60 hours post-irradiation,  and Jursinic17  observed stability 
in the signal to be within 2% at 2.5 days after irradiation.  Viamonte et al.13 reported no loss of signal 
within the first six hours after irradiation, a 2 % signal loss within the first five days, and a stable 
signal from five days to 21 days post-irradiation.  Schembri and Heijmen14 observed a fading of the 
OSL signal of less than 1.8% over a 3 week time period.  Needless to say, the fading characteristics of 
the OSLD have been studied exhaustively and the conclusion is that this effect should be accounted 
for in the measurement of dose.   
 The temperature dependence of the OSL has also been investigated and was shown to not 
affect the response of the dosimeters for a temperature range of 10° to 40 °C17.  Each reading of a 
dosimeter decreases the stored charge by a finite amount.  A depletion of the OSL signal with each 
reading of 0.05% has been reported17, and other works have suggested that 0.2% of the signal is lost 
with each reading13,16. 
    Jursinic17 found that when OSL are used repeatedly, going through many cycles of 
irradiation, reading, and annealing, the measurement uncertainty was 0.6%, demonstrating an 
improvement in the precision over using the dosimeter a single time.  He reported that for the single-
use method, the measurement uncertainty was 0.9%.  Yukihara et al.18 reported a similar level of 
uncertainty, 0.7%, for dosimetry in radiotherapy using Al2O3:C dosimeters.  The reported uncertainty 
was for the readout of a single dosimeter, and the uncertainty for the readout of more than one 
dosimeter would decrease with the square root of the number of dosimeters read. 
1.3.3 Measurement of OSL Signal 
 The components necessary to stimulate and capture luminescence in OSLD include a light 
source, filters, and a photomultiplier tube (PMT), as shown below in Figure 1.3.  The light source is 
used to stimulate the trapped charges, and a filter is necessary for the stimulation light to select the 
appropriate wavelengths of light.  The filtered light incident upon the dosimeter provides the energy 
 necessary for the trapped charges to escape and recombine, releasing luminescence.
wavelengths has been found to be the most efficient for stimulating Al
but green light is used instead so that the stimulation light is 
420 nm10.  Both the stimulation light and the luminescence from the relaxation of the excited F
pass through another filter prior to entering the PMT in order to remove
component.  The emitted luminescence enters the PMT, where it is multiplied and counted.
Figure 1.3 Diagram of components for measuring OSLD signal.  
 Several stimulation methods have been investigated to induce luminescence, including 
continuous-wave OSL (CW-OSL) and pulsed OSL (POSL).
method and recommended most frequently.  This method
constant light intensity while collecting the stimulated luminescence
exposing the material to short pulses of stimulation light with a high pulse frequency.  The emitted 
luminescence is then measured in between the light pulses, and not
necessitates discrimination between the stimulation and emitted light, so less filtration is needed 
before the PMT.  This technique requires an underst
that appropriate timing can be selected in order to detect most of the emitted signal and at the same 
time avoid the stimulation light.  The signal collected from the dosimeter is integrated over many 
pulses, and if this method is performed over a longer period, the luminescence versus time curve 
approximates the luminescence versus time curve for CW
 Measurement of the OSL signal can be made using the initial OSL intensity or the total OSL 
signal.  The initial intensity is determined using only a short exposure to the stimulation light, on the 
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order of a second.  Total OSL signal is determined by stimulating all the trapped charges in the 
material, and this process can take a much longer time.  Yukihara and McKeever5 state that the choice 
of measurement technique should not matter, but that the initial OSL intensity is dependent upon the 
stimulation power and is vulnerable to fluctuations in the power.       
1.4 Hypothesis and Specific Aims 
 We hypothesized that the incorporation of OSLDs into the RPC phantoms, regardless of their 
angular dependence, will measure on average equivalent dose measurements as compared to the 
existing TLD measurements within ± 1%.   
 This hypothesis was tested with the following specific aims: 
1. A dosimetry insert for the RPC pelvic phantom was modified to accommodate OSLD and 
TLD adjacent to the planes of film. 
2. Treatment plans of increasing angular beam delivery for the pelvic phantom were developed. 
3. Each developed treatment plan was delivered three times to the pelvic phantom, containing 
two TLD and two OSLD (oriented in the transverse plane) at the center of the PTV, in 
addition to radiochromic film for the IMRT treatments. 
4. The dose measurements from the TLD and OSLD were compared to determine dose 
measurement equivalency, and whether an angular dependence correction factor was needed.   
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Chapter 2 Methods and Materials 
2.1 Phantoms 
2.1.1 Spherical Phantom 
 A spherical phantom was designed and constructed in order to investigate, under the simplest 
of circumstances, the magnitude of the response of the OSLD at varying angles.  The 10 cm diameter 
phantom pictured on the left in Figure 2.1 is made of high-impact polystyrene, with the center of the 
OSLD nano-cassette positioned at the center of the sphere.  A cylinder of 1 cm diameter was milled 
from the base of the sphere, and an insert of the same diameter was made to fit in that space.  The 
cylindrical insert has a slot at the top for holding the OSL at the center of the phantom, and is attached 
to a flat base as shown on the right in Figure 2.1, which has a pin designed to fit into a corresponding 
hole on the phantom for reproducible positioning of the OSL.  
 
Figure 2.1 High-impact polystyrene spherical phantom (left), and phantom base and insert holding 
the OSLD within the spherical phantom (right) 
2.1.2 RPC Pelvic Phantom 
 The RPC’s pelvic phantom was used for this study, which was designed for remote audits and 
credentialing of institutions for participation in clinical trials.  The phantom shell is made of PVC, can 
be filled with water to simulate soft tissue, and is made to estimate the average size and shape of 
patients and organs of interest in the treatment of the prostate as seen in Figure 2.2.   
 Figure 2.2 Axial CT scans of phantom (left) and patient (right) demonstrating similarity of phantom 
The shell contains polybutylene terephthalate (PBT) 
heads, each containing a hollow tube for the insertion of acrylic femoral head rods.  There are two 
imaging rods made of solid acrylic, and two dosimetric rods, 
for the positioning of a TLD capsule at the level of the target.  At t
large diameter tube allows for the placement of the imaging and dosimetric inserts
place within the tube, as seen in Figure 2.
placed along the large tube for motion tracking
CyberKnife treatments. 
Figure 2.3 RPC pelvic phantom shell (left) with dosimetry (middle) and imaging (right) inserts
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 The imaging insert of the phantom contains both a target and organs at risk, made of 
materials to approximate patient tissue densities and CT numbers.  A spherical nylon ball was used 
for the prostate, a polyethylene ball for the bladder, and a cylinder of wax surrounded by a thin 
polyethylene tube was used for the rectum and rectal wall.  The dosimetry insert is made of high-
impact polystyrene, and the cylinder breaks into four quarters for loading dosimeters as seen below in 
Figure 2.4.  Within the target volume of the dosimetry insert, there are two TLD and it was modified 
to hold an additional two OSLD in the axial plane.  The insert also contains film in both the coronal 
and sagittal planes, which are pricked by pins mounted in the insert in spots unique to the phantom, 
and these pin pricks are used for the registration of the film, discussed later in Section 2.6.2. 
 
Figure 2.4 Dosimetry insert split into posterior and anterior half (left), and posterior half split into 
two quarters to show positioning of OSLD and TLD (red circles) at the center of the target (right) 
2.1.3 Slab Phantom 
 The energy dependence of OSLD in full phantom conditions had not yet been characterized 
by the RPC, so the phantom seen below in Figure 2.5 was used to perform irradiations to determine a 
full phantom energy-dependence correction factor for OSLD.  The phantom is made of 15 x 15 cm2 
slabs of high-impact polystyrene, each 2 cm thick, with the exception of one 3 cm thick slab.  One 
slab contained a section in the middle that could slide out and hold a TLD at the center.  A new 
sliding section was made to the exact dimensions of the previous section holding the TLD, but instead 
was made to hold an OSLD nano-cassette centered within the slab.  A piece of high-impact 
polystyrene was then placed on top of the OSLD to eliminate any air gap within the phantom.  A 
single OSLD was placed at a depth of 10 cm.  Beyond the depth of the OSLD, there was 7 cm of 
high-impact polystyrene to provide sufficient backscatter.  Another 2 cm thick section of the phantom 
contained a cylinder bored out of the center to insert an ionization chamber. 
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Figure 2.5 High-impact polystyrene phantom showing section where OSLD placed 
2.2 Treatment Planning 
2.2.1 Phantom Simulation 
 The CT images were acquired using a GE LightSpeed RT16 scanner (GE Healthcare, 
Waukesha, WI).  The phantom shell and dosimetry insert were filled with water, and the acrylic 
imaging rods were placed in the femoral heads.  The phantom was placed on the imaging couch in the 
supine position, in a head first orientation.  The lasers were aligned to place the isocenter near the 
center of the prostate.  The laser lines were marked with tape on the anterior, left, and right sides of 
the phantom.  Radio-opaque markers (bb’s) were placed at the laser crosshairs to mark isocenter.  A 
typical MD Anderson prostate protocol was used for the CT simulation, and the resulting images 
were imported into the Pinnacle treatment planning system for the three co-planar treatments.  The 
pelvic phantom was then imaged on a GE LightSpeed RT16 Xtra scanner at St. Luke’s Episcopal 
Hospital Radiation Therapy and CyberKnife Facility using the same setup procedure and a similar 
scanning protocol, for developing the CyberKnife treatment plan.  The resulting images were 
imported into Accuray’s MultiPlan (Accuray, Sunnyvale, CA) treatment planning system.     
 Figure 2.6 Axial CT image of prostate phantom at the 
 An axial slice of the phantom at the level of the c
The bb placement, indicating isocenter, can be seen on the anterior, right and left sides of the 
phantom in the image. 
2.2.2 Dose Prescription 
 The dosimetric guidelines for this study are based on the dose 
by the RPC Prostate IMRT credentialing protocol.  The protocol specifies that at least 98% of the 
PTV receives a dose of 6 Gy, and a maximum dose of 6.4 Gy may be delivered to less than 2% of the 
PTV.  The bladder, rectum and femoral heads are the critical normal structures, and must not receive 
more than 6.7 Gy.  The normal structure constraints are listed in Table 2.1.
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Structure Dosimetric Constraints 
Bladder 
V5.7 Gy < 50% 
V6.0 Gy < 35% 
V6.3 Gy < 25% 
V6.7 Gy < 15% 
Rectum 
V5.0 Gy < 50% 
V5.7 Gy < 35% 
V6.0 Gy < 25% 
V6.3 Gy < 15% 
Femoral Heads Maximum dose ≤ 6.7 Gy 
Table 2.1 RPC Prostate IMRT normal tissue constraints 
2.2.3 Planning Procedures 
 Treatment planning was performed on Pinnacle v9.0 (Phillips Medical, Madison, WI) and 
MultiPlan v3.5.3 (Accuray, Sunnyvale, CA).  The couch was removed from the images, and the 
treatment isocenter was identified at the intersection of the simulation bb’s.  Contours were created 
for the prostate, bladder, rectum and femoral heads manually using the region of interest (ROI) tool.  
Contours were also created for the TLD in the target and femoral heads, as well as for the OSLD in 
the target.  The external tissue was contoured using the auto-contour function.  Using guidelines set 
by MD Anderson’s Genitourinary (GU) Service, several planning structures were created.  The 
prostate was expanded by 7 mm in all directions, with the exception of a 5 mm posterior expansion, 
to create the PTV.  An additional 5 mm margin was added to the PTV to create a structure called 
‘PTV expand’.  A structure for the normal tissue was created by removing the volume ‘PTV expand’ 
from the external tissue.  Additional planning structures were created, including a 1 cm expansion of 
the PTV, which could be used to achieve coverage of the target, and a rectum avoid structure to bring 
the dose off the anterior wall of the rectum.  The rectum avoid structure was created by subtracting 
the structure ‘PTV expand’ from the contoured rectum.  
 Four treatment plans of increasing angular beam delivery were created for the pelvic phantom 
using common dose prescriptions and constraints described in Section 2.2.2. 
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2.2.3.1 Four Field Box 
 Four coplanar beams were created for this plan, each using 18 MV photons.  The 
anteroposterior (AP) beam had a gantry angle of 0°, a gantry angle of 180° was used for the 
posteroanterior (PA) beam, and gantry angles of 90°and 270° were used for the left lateral and right 
lateral beams, respectively.  The jaws were set to achieve adequate coverage of the PTV, while 
minimizing the dose to the normal tissue.  The couch and collimator angles were set to 0° for all 
beams.  The dose grid encompassed the phantom, and used a resolution of 0.4 cm3.  The final dose 
was computed using the collapsed cone (CC) convolution algorithm.      
2.2.3.2 IMRT 
 The typical beam arrangement for prostate IMRT at MD Anderson uses eight 6 MV photon  
coplanar beams, with the following gantry angles: 225°, 260°, 295°, 330°, 30°, 65°, 100°, and 135°.  
The couch and collimator angles were set to 0° for all beams.  The dose grid encompassed the 
phantom and a resolution of 0.4 cm3 was used.  Initially, each beam was set to be equally weighted 
and unlocked.  Direct Machine Parameter Optimization (DMPO) was used for the inverse planning, 
and was set to allow the computer to set the field size.  The objectives for the plan focused foremost 
on achieving target coverage, achieving the dose constraints to the critical structures, and finally, the 
normal tissue objective was set to deliver a maximum of half the prescription dose to 1% of the 
volume.  The plan was normalized to 97% of the prescribed dose to achieve PTV coverage.  The final 
dose calculation was computed using the CC convolution algorithm. 
2.2.3.3 VMAT 
 Two arcs were created using the dynamic arc beam type in Pinnacle, allowing for variable 
gantry rate, MLC leaf speed, and dose rate.  The couch angle was set to 0° and 6 MV photons were 
used for both arcs.  The dose grid covered the entire phantom and used a resolution of 0.4 cm3.  Each 
beam was given equal weight, with the first arc beginning at a gantry angle of 181° and rotating to 
180° in a clockwise (CW) motion with a 30° collimator angle.  The second arc rotated from 180° to 
181° in a counter-clockwise (CCW) motion with a 330° collimator angle.  SmartArc optimization was 
used, and the computer was allowed to set the field size.  The optimization generated a new control 
point every 4 degrees, and the leaf motion was constrained to prevent the MLC from attempting to 
move too quickly.  The objectives for the plan were similar to those used for the IMRT optimization, 
the most important being target coverage, then trying to meet critical structure dose constraints, and 
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minimizing the dose to the normal tissue.  The plan was normalized to 96% of the prescribed dose to 
achieve PTV coverage.  Final dose was calculated using the CC convolution algorithm.  
2.2.3.4 CyberKnife 
 Using Accuray’s MultiPlan v3.5.3 inverse treatment planning system, a CyberKnife plan was 
created.   The CyberKnife Robotic Radiosurgery System (Accuray, Sunnyvale, CA) utilizes a 6 MV 
compact linear accelerator mounted on a robotic arm, and delivers pencil beams at discrete nodes 
surrounding the patient.  The beam can be collimated by using either a set of interchangeable circular 
collimators, or the Iris™ Variable Aperture Collimator.  The plan for this study used the Iris 
collimator, and limited the cone sizes used from 25 mm up to 60 mm.  The dose grid encompassed the 
phantom, and a high-resolution dose grid was used during the final dose calculation, which performs 
calculations for every voxel in the CT image set.  The objectives for the plan were the same as those 
used for the IMRT optimization, the most important being target coverage and meeting critical 
normal structure constraints.  A minimum number of MU per beam was set.  The ray-tracing 
algorithm was used for the final dose calculation, and the plan was normalized to 90% of the 
prescribed dose.  Sharma et al.22 briefly describes the ray-tracing algorithm method.  This dose model 
uses a combination of off-axis ratios (OAR), tissue-phantom ratios (TPR), collimator output factors 
(OF), and central-axis effective depth calculations to correct for the patient geometry and tissue 
heterogeneities. 
2.3 Phantom Irradiations 
2.3.1 Spherical Phantom Irradiations 
 Irradiations were performed using the spherical phantom described in Section 2.1.1, to 
investigate the angular response of the OSLD under the simplest of circumstances for 6 MV and 18 
MV photon beams.  The irradiations were delivered on a Varian 21EX linear accelerator (Varian 
Medical Systems, Palo Alto, CA) calibrated using the AAPM TG-51 protocol23 and operated in 
service mode.  The phantom was centered on the central axis (CAX) of the beam, and the top of the 
phantom was set to 95 cm SSD.  The field size was set to 5 x 5 cm2, and the collimator angle was 0° 
throughout the irradiation of this phantom.  The monitor units (MU) needed to deliver 100 cGy to the 
OSLD was calculated using Equation 2.1: 
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Equation 2.1 Linac MU calculation 
where D is the prescribed dose per field in cGy, k is the cGy/MU under the reference calibration 
conditions.  DF is the depth factor (PDD for SSD techniques or TMR for SAD techniques), SC and SP 
are the collimator scatter and phantom scatter factors, OAF is the off-axis factor, and AF is an 
attenuation factor, representing any beam attenuators such as wedges or trays. 
 The positioning of the phantom was checked periodically throughout the irradiations.  Three 
sets of irradiations were performed using the spherical phantom, two coplanar irradiations using beam 
energies 6 MV and 18 MV, and one non-coplanar irradiation with a 6 MV photon beam.  
 The dose delivered to each OSLD was calculated using Equation 2.7.  The OSLD calculated 
dose was normalized for all edge-on angles to the face-on angle.  The dose calculated to each 
dosimeter was normalized to the average dose to the dosimeters irradiated at the face-on angle.  A 
statistical analysis of these normalized doses was performed to determine if the response of the OSLD 
at the face-on angle was different from the responses at the edge-on angles.  A one-way analysis of 
variance (ANOVA) test was performed, which is used to compare the means of two or more groups, 
with the normalized dose as the dependent variable and the angle as the factor.  The null hypothesis 
states that the samples in these multiple groups are drawn from the same population.  A p-value less 
than α=0.05 indicated that the null hypothesis could be rejected and the group means were 
significantly different.  After performing the one-way ANOVA, if the null hypothesis was rejected, a 
Fisher’s Least Significant Difference (LSD) test was run to determine which means are statistically 
significantly different from each other.  This test compares the mean of one group with the mean of 
another group using a series of t-tests, the null hypothesis stating that the means of the two groups are 
equal. 
2.3.1.1 Coplanar 6 MV Irradiations 
 The first set of irradiations were delivered with a 6 MV photon beam.  The OSLD response 
with the beam incident normally on the face of the dosimeter (face-on) was compared to the response 
of the dosimeter at varying beam angles in an edge-on orientation around the dosimeter.  The angles 
with respect to the OSLD can be seen below in Figure 2.7.  The edge-on irradiations were done in 45° 
increments around the dosimeter, from 0° to 315°.  For the irradiation of the angles on the inferior 
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half of the dosimeter (225°, 270°, and 315°), the OSLD was rotated 180° within the phantom to 
measure the response of the dosimeter without the influence of the treatment couch and rails.  
 
Figure 2.7 Diagram of OSLD and angles for 6 MV coplanar irradiations.  Angles irradiated continue 
around bottom half of OSLD in edge-on orientation every 45°. 
Three OSLD were irradiated at each angle, and the average response at each angle was normalized to 
the average response at the face-on angle.  For the face-on irradiation, both the gantry and the couch 
were set at 270°.  For all other angles, the couch rotation was set to 0° and the gantry was rotated 
about the phantom.  The setup for the 45° irradiation is shown below in Figure 2.8.   
 
Figure 2.8 Spherical phantom positioned for 45° OSLD irradiations 
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2.3.1.2 Coplanar 18 MV Irradiations 
 The second set of spherical phantom irradiations were performed using an 18 MV photon 
beam, and the response of the OSLD in the face-on orientation was compared to the response of 
several angles around the dosimeter in the edge-on orientation.  The OSLD angles irradiated can be 
seen in Figure 2.9.  The edge-on irradiations were performed every 90° around the dosimeter. 
 
Figure 2.9 Diagram of OSLD and angles for 18 MV coplanar irradiations 
Three OSLD were irradiated at each angle, and the average response for each edge-on angle was 
normalized to the average response for the face-on irradiation.  The gantry and couch angles used for 
the coplanar 6 MV irradiations discussed in Section 2.3.1.1 were also used for this set of irradiations.  
For the angle on the inferior half of the dosimeter (270°), the OSLD was again rotated within the 
phantom to eliminate the effects of the treatment couch and rails.   
2.3.1.3 Non-coplanar 6 MV Irradiations 
 The final set of spherical irradiations was designed to simulate a cone of beam angles similar 
to the angles that might be delivered in a prostate CyberKnife treatment.  The irradiations were 
performed using a 6 MV photon beam.  The response of the dosimeter at varying irradiation angles 
was normalized to the response of the OSLD in the face-on orientation.  The angles irradiated can be 
seen in Figure 2.9.  The angles investigated in the coplanar beam orientation ranged from 0° to 180°, 
as seen on the left in Figure 2.10.  In the non-coplanar beam arrangement, a 90° range of angles 
centered about the top of the OSLD were investigated, with irradiations every 15° as seen on the right 
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in Figure 2.10.  Three OSLD were irradiated at each angle.  The couch rotation was set to 0° for all 
angles, and the gantry was rotated about the phantom. 
 
Figure 2.10 Diagram of OSLD and angles for 6 MV non-coplanar irradiations 
2.3.2 Pelvic Phantom Irradiations 
 To study the angular dependence of the OSLD in full phantom conditions for treatment plans 
of increasing angular beam delivery, the pelvic phantom described in Section 2.1.2 was irradiated.  
The four treatment plans of increasing angular beam delivery are discussed in Section 2.2.3, 
consisting of three coplanar treatments (4-field box, IMRT, and VMAT) and one non-coplanar 
treatment (CyberKnife).  The coplanar treatment plans were delivered on a Varian 21EX linear 
accelerator calibrated using the AAPM TG-51 protocol.  The non-coplanar treatment was delivered 
on the CyberKnife G4 Robotic Radiosurgery System at St. Luke’s Radiation Therapy and CyberKnife 
facility in Houston, TX as shown below in Figure 2.11.  Each plan met the dose prescription and 
critical normal tissue constraints outlined in Section 2.2.2, planned to deliver a target dose of 6 Gy.  
The OSLD batch 06K10 used in this study was only commissioned for linearity corrections up to a 
dose of 3.5 Gy, so the coplanar treatment plans were scaled to deliver a target dose of 3 Gy.  The new 
OSLD batch, 16K12 was then commissioned at the RPC to higher dose levels, allowing the original 
dose prescription to be met.  The CyberKnife treatment and the institution trials, discussed later in 
Section 2.3.2.1, incorporated the new 16K12 OSLD batch, so the original dose prescription of 6 Gy 
was maintained for these deliveries. 
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Figure 2.11 CyberKnife irradiation of pelvic phantom 
 For the treatment plans delivered on the Varian 21EX linacs, the phantom was positioned at 
the head of the couch in the head first, supine orientation.  The lasers were aligned to the simulation 
isocenter using the bb’s and the tape marks, and the positioning of the phantom was checked 
periodically throughout the treatment delivery.  The positioning of the phantom for the CyberKnife 
treatment delivery was accomplished using the fiducials implanted within the phantom shell and the 
CyberKnife’s image guidance system.  The positions of the fiducials are at known coordinates within 
the phantom.  The image guidance system uses two orthogonal fixed x-ray imaging units to image the 
phantom before and throughout treatment delivery, and these images are compared to previously 
generated digitally reconstructed radiographs (DRRs) to determine the positioning and target location, 
and make any necessary adjustments to the phantom position by moving the treatment couch. 
 Each treatment plan was delivered three times, each time loading new dosimeters into the 
phantom before the next irradiation.  The dosimeters included in each treatment deliver varied by 
plan.  For the 4-field treatment, the dosimeters loaded into the phantom included TLD in the target 
and femoral heads, and OSLD in the target volume.  The same dosimeters were loaded into the 
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VMAT and CyberKnife treatments as well.  For the IMRT deliveries, the dosimeters included TLD 
and OSLD loaded in the same manner as the other treatments, as well as radiochromic film in both 
the coronal and sagittal planes through the target volume. 
 During the delivery of the VMAT treatment plans, the rails of the treatment couch were 
moved in and out, as the gantry rotated about the phantom.  For the delivery of the first arc, with the 
gantry rotating about the phantom in the clockwise direction, the rails were out between the angles 
181° and 220°.  At this point, the rails were moved in to the center of the couch as the gantry rotated 
from 220° to 140°.  From 140° to 180°, completing the first arc, the rails were moved back out.  The 
second arc began at 180° and rotated about the phantom in the counter-clockwise direction, and the 
rails were moved in and out during the same angles as for the first arc.  This technique was employed 
to reduce the effect of the rails on the dose delivered to the phantom. 
2.3.2.1 Institution Trials 
 As an additional check, the RPC pelvic phantom was sent to two institutions for irradiation.  
For each institution, the phantom was sent according to RPC credentialing protocol, including 
instructions for simulation, planning, and treatment delivery, and the dosimeters traditionally sent 
(TLD and radiochromic film).  The only change to the standard credentialing process was the 
inclusion of two OSLD, batch 16K12, within the dosimetric insert, as they had been placed during all 
previous irradiations of the pelvic phantom.  One institution performed the RPC credentialing 
protocol for prostate IMRT, and the second institution performed a prostate CyberKnife irradiation.  
Both of these institution trials used the standard RPC prostate dose prescription and normal structure 
constraints. 
2.3.3 Energy Correction Irradiations 
 Using the slab phantom discussed in Section 2.1.3, a set of irradiations was performed to 
investigate the energy dependence of the OSLD in full phantom conditions, and determine an energy 
correction factor.  The irradiations were performed on a Varian 21EX linac using 6 MV and 18 MV 
photon beams.  A TG-51 calibration was performed in a large water phantom.  The surface of the 
water in the phantom was set to 100 cm SSD, with a field size of 10 x 10 cm2, gantry angle of 0° and 
collimator rotation of 0°.  After performing the calibration, the water phantom was replaced with the 
slab polystyrene phantom with the same setup conditions as for the calibration.  Both the calibration 
and the slab phantom irradiation measurements were made with an Exradin A12 (Standard Imaging, 
Middleton, WI) ionization chamber calibrated by the MD Anderson Cancer Center ADCL.  Within 
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the slab phantom, the ion chamber was positioned at a depth of 10 cm.  Three readings were taken per 
beam energy, delivering 200 MU per reading. 
 The readings made for each energy by the ion chamber in the slab phantom at a depth of 10 
cm were used to calculate the dose rate (cGy/MU) to muscle at depth using the AAPM TG-21 
protocol24.  The protocol calculates the dose rate to water at the depth of dmax from measurements 
made in a non-water phantom.  The dose rate was corrected to dose in muscle using a 0.99 correction, 
and the depth was corrected from dmax to 10 cm using the %dd10 for the Varian 21EX. 
 An estimate of the MU needed to deliver 100 cGy to a depth of 10 cm within the polystyrene 
phantom was made by using the percent depth dose (%dd) in water information for the linac at the 
particular energy.  The desired dose was divided by the %dd10 for both 6 MV and 18 MV.  Using the 
slab with the modification for OSLD, a dosimeter was placed at 10 cm depth within the phantom and 
irradiated to the desired MU.  Irradiations were performed for both batches 06K10 and 16K12 OSLD.  
Five OSLD were irradiated for each batch and energy combination, irradiating 20 nanoDots total.  
The response of the OSLD positioned at 10 cm depth within the slab phantom was measured for each 
dosimeter.  The ratio of the dosimeter response at the investigated energy weighted by the expected 
dose delivered to the response from cobalt-60 weighted by its expected dose was found using 
Equation 2.2 shown below: 
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Equation 2.2 Ratio of dosimeter responses to correct for energy dependence 
The terms Avg Corr Rdg, KF, and KL are the same as defined in Section 2.5.  The term DE is the 
expected dose delivered to the dosimeters at the investigated energies (6 MV and 18 MV), which was 
calculated by multiplying the MU delivered, by the dose rate to muscle at a depth of 10 cm as 
calculated using TG-21.   The terms in the denominator of Equation 2.2 all refer to the OSLD 
previously irradiated in cobalt-60 as standards and read during the same session as the OSLD 
irradiated in the slab phantom to establish system sensitivity.  The expected dose delivered to the 
standard dosimeters,  !"#$ , was calculated using an RPC spreadsheet that accounts for the decay of 
the source, irradiation setup, and length of irradiation.  The linearity correction factor for the 
dosimeters irradiated to 100 cGy (standards) is defined to be one. 
 This ratio was calculated for each irradiated dosimeter.  Considering setup and calibration 
errors, we can assume that the irradiations of two batches per energy were actually like irradiations of 
25 
 
the same batch twice.  This assumption is valid based on the RPC OSLD mini-phantom experience.  
The ratios of the dosimeter responses were grouped for the 06K10 and 16K12 batches by energy, and 
an average ratio was calculated per energy (10 dosimeter ratios per energy).  The inverse of the 
averaged ratios for 6 MV and 18 MV was taken to get the energy correction factors for OSLD in full 
phantom conditions. 
2.4 RPC TLD Dosimetry 
 The TLD used in this study were double-loaded cylindrical capsules containing LiF TLD-100 
powder (Quantaflux, LLC, Dayton, OH) from batch B11, each load containing approximately 20 mg 
of powder.  The RPC has already extensively studied the characteristics of this batch of TLD.  The 
correction factors determined by the RPC are used to calculate the absorbed dose to the TLD using 
Equation 2.3:  
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Equation 2.3 TLD dose calculation 
The term Avg Rdg is the average signal measured per unit mass of the powder.  The average reading 
from the powder is multiplied by S, the system sensitivity, and several correction factors unique to the 
TLD batch: KF, KL, and KE.  These factors correct for fading (KF), linearity of the response with dose 
(KL), and the energy dependence (KE) of the dosimeters.   
2.4.1 TLD Batch Correction Factors 
 The fading of the TL signal is corrected using the following equation:  
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Equation 2.4 TLD fading correction factor 
where N = 1.3493, a = 1.2815, b = 0.00010885, c = 0.067810, d = 0.071908, and X is the number of  
days since irradiation.  The TLD are typically read 14 days after irradiation, but no sooner than day 
14. 
 The RPC protocol for calculating the linearity correction is to perform six iterations of the 
calculation to arrive at a final linearity correction value.  The correction for the linearity of the 
response with dose, for a range of doses from 1 to 40 Gy, is calculated using Equation 2.5: 
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Equation 2.5 TLD linearity correction 
For ‘low dose’ irradiations, the response has been shown to be linear, and the constants for  are as 
follows: a = 0, b = -0.000335, and c = 1.1004995.  For ‘high dose’ irradiations, the response of the 
dosimeter exhibits supra-linearity, and the constants become a = 2.55207e-8, b = -2.22110e-4, and c = 
1.064337.  The raw dose is calculated using Equation 2.6: 
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Equation 2.6 TLD raw dose calculation 
where the terms Avg Rdg, S, and KF are the same as those discussed previously. 
 The energy correction factors have been measured for each batch of TLD for a range of beam 
energies for several of the anthropomorphic QA phantoms by the RPC.  Energy correction factors for 
60Co, 6 MV, and 18 MV photon beams are 1, 1.03, and 1.07, respectively. 
2.4.2 System Sensitivity 
  The dosimetry system is the combination of the dosimeters, phantom, and the reader.  The 
system must be calibrated for each reading session because the reader may experience changes in 
sensitivity, which is monitored by reading “standards” and “controls”.  The standard dosimeters are 
irradiated to a known dose from a cobalt-60 unit, and these dosimeters are read at the beginning and 
end of a reading to determine the system sensitivity for the session.  The system sensitivity, S, is 
defined as the expected dose delivered to the standard dosimeters, divided by the average reading, as 
well as fading and linearity corrections.  The control dosimeters are also irradiated by a cobalt-60 
unit, to a different known dose, and are read at the beginning, end, and periodically throughout the 
session.  The purpose of reading the controls is to check the constancy of the system, and track 
changes in sensitivity over time. 
2.5 RPC OSLD Dosimetry 
 The OSLD used in this study were nanoDot™ dosimeters from the InLight® OSL system 
(Landauer, Inc., Glenwood, IL).  The nanoDot dosimeter contains a 5 mm diameter disk-shaped 
sensitive volume of Al2O3:C, 0.2 mm thick.  The disk is enclosed in a light-tight plastic case shown in 
Figure 2.12, measuring 10 x 10 x 2 mm3.  The position of the sensitive volume is indicated on the 
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case by the circle with the center marked by the cross hairs.  Each dosimeter has a unique barcode 
that is scanned prior to being read, and allows for the recording of the associated counts. 
 
Figure 2.12 nanoDot OSLD from Landauer, Inc. 
 The dosimeters are created in batches, and sent to the RPC where the characteristics of the 
batch and each dosimeter are carefully studied.  The dosimeters used in this study came from batches 
06K10, and 16K12, named according to RPC convention.  The dose to the OSLD is calculated using 
Equation 2.7: 
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Equation 2.7 OSLD dose calculation 
The term Avg Corr Rdg is the average counts from the reader, accounting for depletion of the signal, 
multiplied by the element correction factor (ECF), as shown below in Equations 2.8 and 2.9.  The 
element correction factor is discussed in Section 2.5.1. 
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Equation 2.8 Element corrected average reading 
Each dosimeter is read three times in a row, making n = 3 in Equation 2.9, and all dosimeters from an 
irradiation session are read in the same reading session. 
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Equation 2.9 Readings averaged and depletion corrected 
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The system sensitivity, S, described in Section 2.4.2, is determined by the same method for OSLD as 
for TLD.  The average corrected reading is multiplied by the system sensitivity factor, and several 
batch correction factors (KF, KL, and KE).  These batch correction factors are similar in meaning to the 
correction factors used for TLD dosimetry, but the calculation methods differ. 
2.5.1 Element Correction Factor 
 The sensitivity of an individual OSLD varies compared to the population of OSLD within the 
batch of dosimeters, and is corrected for in the dose calculation by the element correction factor 
(ECF).  Each OSLD within a batch are irradiated to a known dose and then read.  The response of a 
single dosimeter at the particular dose level is then divided by the average response of the entire 
population of dosimeters within the batch, resulting in the ECF for that particular OSLD.  The ECF is 
determined at a dose of 25 cGy, and verified at other dose levels.  The sensitivity of OSLD have been 
shown to change with accumulated dose, as discussed in Section 1.3.2, but the RPC has verified that 
for accumulated doses of less than 10 Gy, the average ECF over cycles of irradiation and annealing 
compared to the first ECF determined for the dosimeter are within 0.6% 25.  No dosimeter used in this 
study received an accumulated dose greater than 10 Gy. 
2.5.2 OSLD Batch Correction Factors 
 The fading of the OSL signal after irradiation is corrected using Equation 2.10 for both 
batches 06K10 and 16K12: 
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Equation 2.10 OSLD fading correction factor 
where d is the number of days since irradiation.  The RPC OSL dosimetry protocol requires that the 
dosimeters be read no sooner than five days post-irradiation. 
 The correction for the linearity of the response is calculated using Equation 2.11, which is the 
same as the equation for TLD, but with different constants and the raw dose is calculated in Equation 
2.12 using the average reading that has been corrected by the ECF.  The RPC protocol for calculating 
the linearity correction is to perform six iterations of the calculation to arrive at a final linearity 
correction value. 
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Equation 2.11 OSLD linearity correction 
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Equation 2.12 OSLD raw dose calculation 
As discussed in Section 1.3.2, the linearity of the response of the dosimeter changes with dose.  The 
linearity correction varies between batches.  For the 06K10 batch, the OSLD were commissioned and 
a linearity correction factor was found for doses up to 3.5 Gy.  The response of the dosimeter is linear 
in this dose region, and the constants are a = 0, b = -0.00011579, and c = 1.0116.  The commissioning 
of the OSLD batch 16K12 measured linearity beyond what was studied for the previous batch.  For 
doses up to 15 Gy, the response of the 16K12 dosimeters is supra linear and the constants are a = 
8.34622e-8, b = -2.67355e-4, and c = 1.0259.  
 The energy correction factors have been studied for both batches of OSLD under reference 
point geometry, for use in calculating doses from OSLD irradiated in the RPC mini-phantoms.  The 
energy correction factors for the nanoDot dosimeters have not yet been studied under full phantom 
conditions.  As described in Section 2.3.3, irradiations were performed to determine energy correction 
factors for the OSLD in full phantom. 
2.5.3 microStar™ Reader 
 The microStar™ Reader (Landauer, Inc., Glenwood, IL), shown in Figure 2.13, is currently 
used by the RPC to read OSLD, and was used for this study.  The reader is connected to a computer, 
which is used to control the reader and record data from the dosimeters into a database.  The reader 
uses an array of 38 LED to stimulate the dosimeter, and operates in CW-OSL mode as described in 
Section 1.3.3.  The LED are set to expose the detector for 7 seconds, according to RPC protocol.  A 
‘strong beam’ uses all 38 LED for reading low dose dosimeters, and a ‘weak beam’ uses 6 LED for 
reading dosimeters with high doses; a single LED illuminates the dosimeter before readout to 
determine the dose range6.  The signal from dosimeters that have been irradiated to greater than 200 
cGy saturate the optical detector circuits when illuminated with the strong beam, but using the weak 
beam, the dosimeters can receive a dose up to about 15 Gy before the optical detector is saturated15.   
 The light produced by the LED bank in the reader is filtered by an OG-515 (Melles Griot, 
Rochester, NY) band-pass filter.  Prior to reaching the PMT, the stimulation and luminescence 
photons are differentiated using a combination of Schott BG-12 (Schott, Mainz, Germany) and Hoya 
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B-370 (Hoya, San Jose, CA) colored glass filters.  The LED and OG-515 filter combination has a 
peak transmission near 530 nm, and the combination of the PMT filters have a transmission peak at 
385 nm26.  
 
Figure 2.13 microStar reader, adapter, and control computer 
 Before reading the OSLD, the reader is turned on and allowed to warm up at least 30 minutes 
prior to the session.  Several quality control checks are performed on the reader, measuring the 
electrical noise of the system, the counts measured from just the LED, and the counts measured from 
a calibration source in the detector.  The system sensitivity is determined and monitored according to 
the procedure described in Section 2.4.2.  To begin reading the OSLD, the barcode of the dosimeter is 
scanned and it is inserted into the adapter shown in Figure 2.13.  The adapter holds the nanoDot in 
place within the drawer of the reader, and when the drawer is shut, the adapter opens the dosimeter to 
expose the active volume to the light source.  The counts measured by the PMT are recorded, and the 
OSLD can be removed from the reader. 
2.5.4 Signal Depletion 
 The finite decrease in charge stored by the dosimeter with each reading was referred to in 
Section 1.3.2, and RPC OSL dosimetry includes a correction to account for this signal depletion.  The 
depletion correction for the mth reading (DCm) is calculated using Equation 2.13: 
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Equation 2.13 OSLD depletion correction 
where a = -5.148e-6, b = -1.277e-3, c = 1, and for a dosimeter read three times, m = {0…2}. 
2.5.5 Optical Bleaching 
 The optical bleaching (annealing) of the OSLD at RPC is performed using the cabinet shown 
below in Figure 2.14.  Within the cabinet, there are four 54-watt fluorescent bulbs; two bulbs are 
fixed at the top of the cabinet and two are positioned at the bottom.  To remove any UV photons from 
the light, a filter is placed around each bulb.  Positioned centrally between the top and bottom light 
sources lies a clear acrylic shelf on which the OSLD are placed.  The dosimeters are opened, and the 
active volume is exposed to the light for 24 hours before they are closed and removed from the box. 
 
Figure 2.14 Cabinet for optical bleaching of OSLD at the RPC 
2.6 RPC Film Dosimetry 
 Radiochromic film is favorable for measuring relative dose distributions because of their high 
spatial resolution, insensitivity to visible light, they are nearly tissue equivalent, and they color 
directly, eliminating the need for processing.  The image formation occurs as a dye-forming or 
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polymerization process, and the image is stable over a range of temperatures.  The humidity during 
irradiation also has little impact on the film27. 
 Gafchromic EBT2 film (Ashland, Wayne, NJ) was used in this study, from lot number 
A0521102 with an expiration date of May 2013.  The RPC uses radiochromic film as a part of the 
remote audit program, and has already investigated the dose response of this lot of film and 
performed a film calibration for the dose range of 0 to 30 Gy.  The dose-response curve generated by 
the RPC for this batch of film fits the third-order polynomial shown below in Equation 2.14, 
establishing a relationship between dose and optical density (OD): 
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Equation 2.14 Calibration curve for Gafchromic EBT2 film, lot # A05261102 
For each IMRT irradiation in this study, the pieces of film were cut from the same sheet using a 
template, and all sheets of film were from the same film lot.  One piece was cut for the coronal film, 
and the sagittal film was cut in two parts.  Each piece of film was marked for orientation.  The care 
and evaluation of the film was performed according to the recommendations of AAPM TG-55, which 
include storing the film in a dark and dry place at room temperature, visually inspecting the film 
before irradiation, careful handling of the film, and reading the film at least 48 hours after irradiation 
to minimize the effects of self-development27. 
 The active layer of the EBT2 film is situated between two polyester layers, making it possible 
to be submerged in water for short time periods, and includes a yellow marker dye to minimize 
differences in film responses due to small variations in thickness of this layer.  This marker dye also 
has the benefit of making the EBT2 film less sensitivity to ambient light.  When the film is irradiated, 
the elements in the active layer react and form a blue polymer that appears green due to the presence 
of the yellow marker dye.  The irradiated film has an absorption peak at 636 nm, and 585 nm.  
According to the manufacturer, the film is designed for a wide dose range (1 cGy to 40 Gy), and has 
an effective atomic number of 6.84, demonstrating a difference in response of about 10% in the keV 
to 6 MV photon energy range.  A recent study investigating the energy dependence and dose response 
of the EBT2 films found that the energy dependence of the film was lower than that suggested by the 
manufacturer, showing that the response of the film varied by approximately 4.5% over an energy 
range of 75 kVp to 18 MeV photons28.  This study also reported that the self-development of the film 
was the fastest during the first 48 hours after the film was irradiated. 
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2.6.1 Film Scanning 
 To evaluate the dose distribution measured, the films were scanned using a CCD100 
Microdensitometer (Photoelectron Corporation, Lexington, MA) as shown below in Figure 2.15.  The 
scanner uses an LED light bed, with a wavelength of 665 nm, and a CCD camera placed above the 
film to measure and record the transmission of light.  The height of the CCD was set so that the 
camera focused on a 200 x 200 mm2 area where the films would be placed, and the remaining area of 
the light was covered with a black mask.  This system is contained within a cabinet to prevent 
measurement of room light.  A blank piece of film from the same lot was scanned and used to 
measure the ‘flat field’, and then a grid of known size and spacing was scanned to assign a spatial 
calibration.  Following these calibrations, the films from the IMRT irradiations were scanned in a 
consistent orientation.  The coronal film was scanned, and then the two pieces of the sagittal film 
were placed together and scanned.  The images were saved as 16-bit .FIT files. 
 
Figure 2.15 Setup of microdensitometer used for film scanning 
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2.6.2 Registration 
 The measured dose distribution from the film is compared to the reported dose distribution 
from the treatment planning system (TPS), and to do this, the film and the plan must be registered to 
the same phantom coordinate system.  Using a MATLAB (The MathWorks, Inc., Natick, MA) 
program known as the Computational Environment for Radiotherapy Research (CERR) (J.O. Deasy 
and Washington University, St. Louis, MO), the treatment plan can be registered to the phantom 
coordinate system.  From the TPS, the plan, CT image set, composite dose information, and structures 
are all exported in DICOM-RT format into CERR.  On the CT images, a set of registration points are 
identified, which registers the plan to the phantom.  Using another MATLAB program, RPCFILM, 
the films can be registered to the phantom coordinate system.  The .FIT files created after scanning 
the film, as discussed in Section 2.6.1, are opened in RPCFILM.  The phantom type and number are 
identified, and the pinpricks are identified on the image.  The location of the pinpricks are unique to 
each phantom, and this registers the film to the phantom coordinate system.  After both the film and 
the treatment plan have been registered to the phantom coordinate system, RPCFILM evaluates the 
goodness of fit and calculates RMS error values for the film registration and plan registration, called 
‘RMS Error’ and ‘RMS 3D’, respectively.  To minimize error, the RPC prefers an ‘RMS Error’ of 0.3 
mm or less for one piece of film, such as the coronal film in this study, or 0.5 mm or less for two 
pieces of film, such as the sagittal films in this study.  The limit for ‘RMS 3D’ is set at 1 mm.   
 The dose-response curve for the film batch is then used to calculate the measured film dose 
from the OD values.  The film doses are then normalized to the TLD dose measured in the PTV.  For 
this study, film analysis was performed only for the three IMRT irradiations as well as for the two 
institution trials (one IMRT, one CyberKnife).  For each irradiation, the films were normalized to the 
PTV TLD doses, as well as to the corrected PTV OSLD doses and then compared, as discussed in 
later sections.   
2.7 Dosimetric Evaluation 
 To evaluate the ability of the OSLD to measure on average the same dose as the TLD, the 
TLD and OSLD dose measurements from the pelvic phantom irradiations were compared in several 
ways.  The absolute doses from the TLD and OSLD, the dose profiles normalized by the TLD and 
OSLD doses, and the gamma analysis of the film normalized to both TLD and OSLD were compared. 
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2.7.1 Absolute Dose 
 For the pelvic phantom irradiations, the dose measured in the target volume for the TLD and 
the OSLD were compared.  The locations of the TLD and OSLD within the target can be seen below 
in Figure 2.16.  The doses measured by the two TLD within the target were calculated using the 
method described in Section 2.4, and then averaged.  The dose measured by the two PTV OSLD were 
calculated using the method described in Section 2.5, averaged, and then multiplied by a correction 
factor obtained from the spherical phantom for the appropriate irradiation.  The OSLD dose 
multiplied by the correction factor is referred to as the corrected OSLD dose.  The TLD dose was 
compared to the OSLD dose, as stated in the hypothesis.  A ratio of TLD dose to corrected OSLD 
dose for each pelvic phantom irradiation was calculated, and the average TLD to OSLD dose ratio 
was calculated.  The TLD dose within the femoral heads was not compared to any OSLD doses, as 
there were no OSLD placed within the structure.   
 
Figure 2.16 Diagram of inferior view of the dosimetry insert showing positions of TLD and OSLD 
active volumes within the target 
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2.7.2 Dose Profiles 
 Using the RPCFILM program, dose profiles through the PTV were obtained for both the 
coronal and sagittal films.  For the coronal films, dose profiles were recorded in the lateral and 
superior-inferior directions.  The lateral profile was taken through the PTV, and the superior-inferior 
profile was taken through the PTV and the bladder.  On the sagittal films, dose profiles were recorded 
in the anterior-posterior (AP) and superior-inferior directions.  The AP profile was taken through the 
PTV as well as through the rectum.  The superior-inferior profile included the dose through the PTV 
and through the bladder.  The superior-inferior dose profile for the sagittal films was offset from the 
center in the AP direction by 2 mm to avoid the gap where the two pieces of the sagittal film were 
positioned together for scanning.  The film was sampled every 0.3 mm to create the dose profiles, and 
a 3 mm moving average was used to smooth the data obtained for the profiles. 
 The dose profiles were created after the film was normalized to the TLD target doses and the 
corrected OSLD target doses.  Each profile was plotted displaying the dose calculated by the TPS, the 
normalized film dose, and either the TLD dose or the corrected OSLD dose.  The dose profiles 
resulting from both the TLD and OSLD normalized doses were compared. 
2.7.3 Gamma Analysis 
 Gamma analysis is a quantitative method described by Low et al.29 for comparing dose 
distributions measured by film to those generated by the treatment plan, using the measured 
distribution as the reference information.  This technique evaluates the dose difference between 
measured and calculated, and the distance to agreement (DTA), combining the comparisons into a 
single numerical index called the gamma (γ) index.  A set of criteria for dose difference and DTA are 
established for acceptance, each having equal significance in the calculation of the index.  The 
acceptance criteria for dose difference and DTA form an ellipsoid surface, with the measurement 
point at the origin.  For each pixel, the dose difference and DTA are calculated and a vector is formed 
from the origin to the calculated point.  If the magnitude of the normalized vector is less than or equal 
to one, the calculated point lies within the ellipsoid, passing the criteria with γ ≤ 1.   
 For this study, the Matlab program RPCFILM was used to perform the gamma analysis for 
each plane of film within the phantom.  The criteria established for the RPC pelvic phantom is 7% 
dose difference and 4 mm DTA (7%/4 mm) for both the sagittal and coronal films, with at least an 
85% pixel pass rate.  RPCFILM includes a masking tool which allows for the designation of areas on 
the film to not be included in the analysis, such as pin pricks, the junction of the two sagittal films, or 
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any other film imperfections or artifacts.  An example of area masking on a sagittal film can be seen 
below in Figure 2.17.  RPC protocol for the pelvic phantom analysis is to use a 10 x 10 cm2 area of 
the film for evaluation.  
 
Figure 2.17 Masks applied to a sagittal film before gamma analysis 
 As discussed in Section 2.6.2, the films are normalized to the TLD target dose before analysis 
is performed.  For this study, the films were also normalized to the corrected OSLD target dose and 
an additional gamma analysis was completed.  The gamma results from the TLD normalization and 
OSLD normalization were compared. 
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Chapter 3 Results and Discussion 
3.1 Treatment Planning 
 Four treatment plans of increasing angular beam delivery were developed as discussed in 
Section 2.2, each meeting the dose prescription and normal tissue constraints outlined in the RPC 
prostate IMRT credentialing protocol.  For the three treatment plans developed in Pinnacle, the PTV, 
prostate, bladder, rectum, and femoral heads are represented by the purple, blue, yellow, green, and 
pink contours, respectively.  The CyberKnife plan developed in MultiPlan displays the PTV, prostate, 
bladder, rectum  contours as orange, coral, light blue, and green.  The femoral heads are displayed as 
the pink and dark blue contours, representing the left and right femoral heads.  The four treatment 
plans and their dose-volume histograms (DVH) are displayed below for the same CT slice, at the 
level of the simulation isocenter.  As discussed in Section 2.3.2, the three coplanar treatment plans 
delivered a target dose of 3 Gy, while the CyberKnife plan delivered a target dose of 6 Gy. 
3.1.1 Four Field Box 
 The isodose lines and the DVH generated by the 4-field treatment plan in the pelvic phantom 
can be seen below in Figure 3.1.  The prescription dose of 3 Gy covers 99% of the PTV and 100% of 
the prostate volume.  The normal tissue constraints are met, but the 4-field treatment does deliver a 
higher dose to the critical structures than the subsequent plans.   
 
Figure 3.1 Four field isodose coverage (left) and DVH (right) for the prostate phantom.  The PTV, 
prostate, bladder, rectum, and femoral heads are displayed as purple, blue, yellow, green, and pink, 
respectively. 
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3.1.2 IMRT 
 The IMRT treatment plan for the pelvic phantom isodose plot and DVH can be seen in Figure 
3.2.  The target prescription dose of 3 Gy covers 99% of the PTV and achieves complete coverage of 
the prostate volume.  As seen in the DVH, the dose to the femoral heads, bladder, and rectum are all 
lower than for the 4-field box treatment. 
 
Figure 3.2 IMRT isodose coverage (left) and DVH (right) for prostate phantom.  The PTV, prostate, 
bladder, rectum, and femoral heads are displayed as purple, blue, yellow, green, and pink, 
respectively. 
3.1.3 VMAT 
 The isodose coverage and DVH generated for the pelvic phantom VMAT treatment plan can 
be seen below in Figure 3.3.  The prescription dose of 3 Gy covers 99% of the PTV and 100% of the 
prostate, meeting the dose prescription outlined previously.  Similar to the IMRT treatment, the doses 
received by the normal structures are lower compared to the 4-field treatment. 
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Figure 3.3 VMAT isodose coverage (left) and DVH (right) for prostate phantom.  The PTV, prostate, 
bladder, rectum, and femoral heads are displayed as purple, blue, yellow, green, and pink, 
respectively. 
3.1.4 CyberKnife 
 The isodose lines and DVH generated by the CyberKnife plan developed in MultiPlan for the 
pelvic phantom can be seen below in Figure 3.4.  The prescription dose of 6 Gy covers 99.8% of the 
PTV and 100% of the prostate volume.  The bladder and rectal dose were higher for the CyberKnife 
treatment than for either the IMRT or VMAT treatment plans. 
    
Figure 3.4 CyberKnife isodose coverage (left) and DVH (right) for prostate phantom.  The PTV, 
prostate, bladder, and rectum are displayed as orange, coral, light blue, and green.  The left and right 
femoral heads are represented by the pink and blue contours, respectively. 
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3.2 Phantom Irradiations 
3.2.1 Spherical Phantom Irradiations 
 The irradiations of the spherical phantom were carried out according to the setup described in 
Section 2.3.1.  The MU needed  to deliver 100 cGy to a depth of 5 cm on CAX, for a field size of 5 x 
5 cm2 for photon beams of energy 6 MV and 18 MV were calculated using Equation 2.1, and are 
shown below in Equations 3.1 and 3.2, respectively.  For both beam energies, there is no off-axis 
factor (OAF) and there were no trays or wedges attenuating the beam.  The depth factor used for these 
calculations was Tissue Maximum Ratio (TMR), since the phantom irradiation was performed using 
the SAD technique.  The MU necessary to deliver the desired dose at 6 MV was calculated to be 114 
MU, and 101 MU at 18 MV.   
   
100 .KL
1.03 MNOPQ  ·  0.905 · 0.962 · 0.983
 114  
Equation 3.1 MU calculation for 6 MV spherical phantom irradiation 
   
100 .KL
1.067 MNOPQ  ·  1.001 · 0.943 · 0.982
 101  
Equation 3.2 MU calculation for 18 MV spherical phantom irradiation 
 The dose delivered to each OSLD was calculated using Equation 2.7.  The normalized OSLD 
responses for the coplanar 6 MV spherical phantom irradiations can be seen below in Figure 3.5.  The 
error bars for each data point represent the standard error (SE).  The null hypothesis of the one-way 
ANOVA test was rejected (p-value = 0.000), showing that the mean of at least one angle response 
was different from the other mean responses.  The Fisher’s LSD test determined that the response of 
the dosimeter at the face-on angle was statistically significantly different from all other angles at the 
α=0.05 level 
 An additional ANOVA was performed including only the edge-on angular responses, and the 
resulting p-value of 0.124 shows that the null hypothesis cannot be rejected.  The responses at these 
angles cannot be from different populations, therefore the responses can be grouped together.  
Knowing this, the normalized responses for all edge-on angles were averaged, and the average was 
calculated to be 0.961 and is indicated on the graph as the red horizontal line.   
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Figure 3.5 OSLD response for coplanar 6 MV spherical phantom irradiations 
 For the coplanar 18 MV spherical phantom irradiations, the normalized OSLD responses can 
be seen below in Figure 3.6.  The error bars represent the standard error for each angular response.  
The noticeably larger error for the average dose at 180° is due to one of the three OSLD irradiated at 
that angle being either a bad OSL, or there was an error in the irradiation of the dosimeter, so that 
data was not included in the calculation of the average dose, nor the standard error.  The responses of 
the dosimeters at the varying angles were found to be statistically significantly different (p-value = 
0.006) after running one-way ANOVA.  The Fisher’s LSD test showed that the OSLD response for 
the face-on angle was statistically significantly different from the edge-on angular responses.  A 
second ANOVA test, comparing only the edge-on angular responses showed that there is no 
difference in response between the angles (p-value = 0.425).  The average edge-on normalized OSLD 
response, indicated by the red horizontal line on the graph, was calculated to be 0.981.   
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Figure 3.6 OSLD response for coplanar 18 MV spherical phantom irradiations 
 The normalized OSLD responses from the non-coplanar 6 MV spherical phantom 
irradiations, specific to CyberKnife, can be seen in Figure 3.7.  The error bars for each data point 
represent the standard error.  A statistically significant difference was found between the different 
angles irradiated (p-value = 0.000), and the Fisher’s LSD test determined that the response of the 
dosimeter at the face-on angle was statistically significantly different from the responses for all 
remaining angles.  An additional ANOVA was performed, excluding the face-on response, and the 
resulting p-value of 0.006 shows that the null hypothesis can be rejected and the responses of these 
angles are from different populations and the means of the angular responses are not equal.  The 
average edge-on dosimeter response was still calculated, and found to be 0.963 as shown by the red 
horizontal line on the graph.   
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Figure 3.7 OSLD response for non-coplanar 6 MV spherical phantom irradiations 
 For each spherical phantom irradiation, the average normalized response of the dosimeters in 
the edge-on orientation was determined.  The averaged doses measured by the dosimeters in the edge-
on orientation relative to the doses measured when the beam was incident normally on the face of the 
dosimeter for the coplanar spherical phantom irradiations were 0.961 and 0.981, for 6 MV and 18 MV 
photon beams, respectively.  These results demonstrate an under-response of the OSLD of 
approximately 4% for 6 MV, and 2% for 18 MV.  The coplanar spherical phantom irradiation results 
are in agreement with the data published by Kerns et al.3, which demonstrated a decrease in the 
OSLD response of 4% for 6 MV photon beams parallel to the surface of the dosimeter.  The angular 
response at 6 MV of the nanoDot dosimeter normalized to the dosimeter response at 0° reported by 
Kerns can be seen below in Figure 3.8, demonstrating the approximately 4% decrease in response of 
the dosimeter for the edge-on irradiations (90° and 270°).  It is important to note that the orientation 
of the nanoDot within the pelvic phantom for the Kerns study is not the same as the orientation used 
in this study, and as such, only the responses at 0°, 90°, and 270°are applicable for comparison.    
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Figure 3.8 Angular response of OSLD at 6 MV normalized to response at 0°, error bars represent the 
coefficient of variation (Kerns et al.), copied with permission from AAPM. 
 The decrease in response of 2% for the 18 MV coplanar spherical phantom irradiations 
observed in this study is slightly higher than the decrease in response of 3% for the edge-on 
irradiations reported by Kerns, which can be seen below in Figure 3.9.  The increased response 
observed in this study for 18 MV coplanar photon beams compared to the Kerns study, going from an 
under-response of 3% to 2%, could be attributed to differences in the phantoms used.  The decrease in 
response of 2% for the OSLD was measured in the small, spherical phantom from this study, whereas 
the under-response of 3% reported by Kerns was measured in the RPC’s pelvic phantom.  The scatter 
conditions provided by the two phantoms are different, and as discussed in Section 1.1, the scatter 
component is important to the dose deposited in the OSLD.  While the small differences in responses 
observed at 18 MV (2 % vs. 3%) may be due to the phantoms, the responses may be the same within 
experimental uncertainties.  However, the trend of an increase in response from 6 MV to 18 MV 
photon beams that was shown by Kerns is supported by the results of this study.  
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Figure 3.9 Angular response of OSLD at 18 MV normalized to the response at 0°, error bars 
represent the coefficient of variation (Kerns et al), copied with permission from AAPM. 
 The averaged dose measured by the dosimeters normalized to the dose measured in the face-
on orientation for the non-coplanar 6 MV spherical phantom irradiations was 0.963, demonstrating a 
4% under-response of the dosimeter.  However, the ANOVA results indicate that the normalized 
responses at all the investigated non-face-on angles are not from the same population, so averaging 
the responses may not be an appropriate method of determining the angular response of the OSLD.  
 The inverse of the average normalized responses was then taken to determine the angular 
correction factors to be used for adjusting the OSLD measured dose for the pelvic phantom 
irradiations.  The angular correction factors calculated can be seen below in Table 3.1.  These factors 
were applied to the OSLD measured dose from the pelvic phantom irradiations, as shown in Section 
3.3 for the absolute dose, dose profiles, and gamma analysis comparisons. 
 
Angular Correction Stdev 
Coplanar 6 MV 1.040 0.007 
Coplanar 18 MV 1.019 0.004 
Non-coplanar 6 MV 1.038 0.009 
Table 3.1 Angular correction factors and standard deviations from spherical phantom irradiations 
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3.2.2 Pelvic Phantom Irradiations 
 Irradiations of the RPC pelvic phantom were carried out according to the setup discussed in 
Section 2.3.2.  Each treatment plan was delivered three times, and the doses measured from both the 
TLD and the OSLD for each coplanar treatment plan (4-field, IMRT, VMAT) can be seen below in 
Figure 3.10.  The error bars for each data point represent the standard error.  The TLD dose was 
calculated using Equation 2.3, and the dose delivered to the OSLD was calculated using Equation 2.7.  
The doses measured by the two TLD in the PTV were averaged, as well as the doses from the two 
OSLD in the PTV, to represent a single dose delivered to the center of the PTV in the phantom.  The 
OSLD measured dose, not corrected for angular dependence, is shown to be consistently lower than 
the doses measured by the TLD in the pelvic phantom for the coplanar irradiations.  The under-
response of the OSLD compared to the TLD is shown to be greater for the 6 MV IMRT and VMAT 
irradiations, than for the 18 MV 4-field irradiations, consistent with the spherical phantom results 
shown in Section 3.2.1.  The average percent differences between the TLD measured dose and 
uncorrected OSLD measured dose for the 4-field, IMRT, and VMAT irradiations were calculated to 
be 1.9%, 3.0%, and 3.3%, respectively.      
 
Figure 3.10 TLD and OSLD doses from 3 Gy coplanar pelvic phantom irradiations 
 The doses measured by the TLD and OSLD in the PTV of the pelvic phantom for the 
CyberKnife irradiations performed can be seen below in Figure 3.11.  The data for the TLD doses and 
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OSLD doses are offset from each other in the x-direction for clear visualization of the data points and 
their associated errors.  The error bars for each dose represent the standard error.  Again, the TLD and 
OSLD doses were calculated using Equations 2.3 and 2.7, respectively.  The doses measured by the 
two target TLD were averaged to represent a single dose delivered to the center of the prostate.  The 
same averaging was done with the two target OSLD doses.  In the pelvic phantom, the OSLD, not 
corrected for angular dependence, once again under-responded for the non-coplanar treatment as 
compared to the response of the TLD.  The average percent difference between the TLD measured 
dose and uncorrected OSLD measured dose was calculated to be 1.1% for the three CyberKnife 
irradiations.  However, the doses measured by the OSLD, not corrected for angular dependence, for 
the three CyberKnife irradiations were closer to the doses measured by the TLD than expected.  Many 
of the beams in the CyberKnife deliveries were from angles superior and inferior to the edge-on 
angles, so the angular correction is not as great as for the gantry based, coplanar deliveries. 
 
Figure 3.11 TLD and OSLD doses from the three 6 Gy non-coplanar pelvic phantom irradiations 
 As discussed in Section 2.3.2.1, the prostate phantom was sent to two different institutions to 
evaluate the response of the OSLD in the phantom.  One institution delivered a standard prostate 
IMRT treatment, and the second institution delivered a CyberKnife treatment.  The doses measured 
by the target TLD and OSLD in the pelvic phantom for both institution trials can be seen below in 
Figure 3.12.  The error bars for each dose represent the standard error.  The doses measured by the 
TLD were calculated using Equation 2.3, and the dose measured by the OSLD was calculated using 
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Equation 2.7.  The doses from the two TLD were averaged, and the doses from the two OSLD were 
averaged to represent a single dose to the PTV.  For each institution trial, the uncorrected OSLD dose 
was lower than the TLD dose.  The percent differences between the TLD measured dose and 
uncorrected OSLD measured dose were 4.4% and 3.4% for the IMRT and CyberKnife institution 
trials, respectively.  For the CyberKnife trial, the OSLD measured dose was much lower compared to 
the TLD measured dose and consistent with the response expected from the non-coplanar spherical 
phantom irradiations, but contrary to the CyberKnife results shown in Figure 3.11 (1.1% difference as 
compared to 3.4%).  As mentioned previously, the majority of the beam angles for the CyberKnife 
irradiation were incident on the OSLD at angles superior and inferior to the edge-on angles, which 
would result in a lower angular correction than for the coplanar deliveries, but this was not observed 
for the CyberKnife trial. 
 
Figure 3.12 TLD and OSLD doses from 6 Gy institution trials  
 Comparison of the TLD and OSLD measured doses, as well as the corrected OSLD doses 
using the values presented in Table 3.1, is performed later in Section 3.3.1. 
3.2.3 Energy Correction Irradiations 
 The irradiations necessary to determine the energy correction factors for OSLD in full 
phantom conditions were performed as described in Section 2.3.3.  Ion chamber measurements in the 
polystyrene slab phantom were made at a depth of 10 cm, the depth where the OSLD would later be 
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placed, for the calculation of dose rate and dose delivered to the OSLD.  Three ion chamber readings 
were made for the two beam energies, and the results can be seen below in Table 3.2. 
Beam Energy Reading 1 (nC) Reading 2 (nC) Reading 3 (nC) 
6 MV 26.69 26.68 26.68 
18 MV 31.85 31.84 31.84 
Table 3.2 Ion chamber measurements in slab phantom at depth of 10 cm for 6 MV and 18 MV 
photon beams 
 These ion chamber readings were used to calculate the dose rate to water at a depth dmax using 
the TG-21 protocol, and making corrections for the dose rate to muscle at a depth of 10 cm.  The dose 
rate to water at dmax was calculated to be 1.016 RSTUV for 6 MV, and 1.027  
RST
UV
 for 18 MV.  The TG-21 
worksheets for the two beam energies can be found in the Appendix, in Section 5.1.  The calculations 
for the dose rate to muscle at a depth of 10 cm for beam energies 6 and 18 MV can be seen below in 
Equations 3.3 and 3.4, respectively. 
W @XYMZ[)6 10 .A  1.016 
.KL

 · 0.99 ·
66.3
100
 0.667 
.KL

 
Equation 3.3 Dose rate to muscle at a depth of 10 cm for 6 MV photon beam 
W @XYMZ[)6 10 .A  1.027 
.KL

 · 0.99 ·
80.7
100
 0.821 
.KL

 
Equation 3.4 Dose rate to muscle at a depth of 10 cm for 18 MV photon beam 
 The MU estimated to deliver 100 cGy to a depth of 10 cm in the phantom was calculated for 
6 MV and 18 MV, and can be seen in Equations 3.5 and 3.6, respectively.  These MU settings were 
used to deliver approximately the desired dose to the OSLD at depth in the polystyrene phantom, as 
the %dd data is specified to water. 
   
100 .KL
66.3 100⁄
 151  
Equation 3.5 MU calculation to deliver approximately 100 cGy to OSLD for 6 MV photon beam  
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   
100 .KL
80.7 100⁄
 124  
Equation 3.6 MU calculation to deliver approximately 100 cGy to OSLD for 18 MV photon beam  
 The ratio of the dosimeter response at the designated energy to the response for cobalt-60 was 
calculated as described in Section 2.3.3.  Standard dosimeters were read for both the 06K10 and 
16K12 OSLD batches, for which the expected dose delivered is 100 cGy.  The average corrected 
reading (Avg Corr Rdg) for the 06K10 standards was calculated to be 434,931, which represents the 
raw PMT counts that have been depletion corrected and multiplied by the ECF for each dosimeter, as 
described in Section 2.5.  The average corrected reading for the 16K12 standards was calculated to be 
366,210.  The fading correction factor (KF) was calculated for all OSLD using Equation 2.10, and the 
fading correction factor for the standards from batch 06K10 can be seen below in Equation 3.7.  The 
fading correction factor for batch16K12 standards, which were read 7 days after irradiation, was 
calculated using this same equation to be 1.009064. 
   
1
1.005 · 6*.?1
 1.007945 
Equation 3.7 Fading correction factor for dosimeters read 6 days post-irradiation 
The expected dose delivered to the standard dosimeters was calculated using the RPC spreadsheet, 
and was found to be 100.095 cGy. 
 For each dosimeter irradiated, the average corrected reading, fading correction factor, and 
linearity correction factor was calculated.  The linearity correction factor was calculated using 
Equation 2.11 for both 06K10 and 16K12 dosimeters.  The expected dose delivered to the standard 
dosimeters for 6 MV and 18 MV was calculated as shown below in Equations 3.8 and 3.9, 
respectively. 
 P\  151  · 0.667 
.KL

 100.72 .KL 
Equation 3.8 Expected dose delivered to OSLD for 6 MV photon beam 
8] P\  124  · 0.821 
.KL

 101.8 .KL 
Equation 3.9 Expected dose delivered to OSLD for 18 MV photon beam 
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 The ratio of dosimeter responses, calculated using Equation 2.2, was calculated for each 
irradiated OSLD.  The ratios of the five 06K10 OSLD irradiated at 6 MV, and the ratios of the five 
16K12 OSLD irradiated at 6 MV were averaged to produce an energy correction factor for the OSLD 
at 6 MV.  The same averaging was done for the five 06K10 dosimeters and five 16K12 dosimeters 
irradiated at 18 MV.  The inverse of the two ratios, one for each of the two beam energies, was taken 
to calculate the energy correction factors.  The energy correction factors for OSLD in full phantom 
conditions, calculated for photon beam energies 6 MV and 18 MV can be seen below in Table 3.3.  
These energy correction factors were used in the calculation of OSLD dose as described in Section 
2.5. 
Beam Energy KE Stdev 
6 MV 1.02 0.010 
18 MV 1.08 0.011 
Table 3.3 Energy correction factors for OSLD in full phantom conditions 
 The calculated energy correction factors for OSLD in full phantom conditions are very close 
to the correction factors for TLD in full phantom, 1.03 and 1.07 for 6 MV and 18 MV photon beams, 
respectively.  A decrease in response of the OSLD for the energies of 6 MV and 18 MV was 
observed, with a higher decrease for the 18 MV beams, as also observed for TLD.  This result is 
consistent with the results of Viamonte et al. 13 in that there was a decrease in response of the OSLD 
at higher energies.  Viamonte showed that for dosimeters calibrated in a 60Co beam, there was an 
observed decrease in sensitivity of 4%, although a 4% decrease in response was observed in this study 
for neither 6 MV nor 18 MV.     
3.3 Dosimetric Evaluation 
3.3.1 Absolute Dose 
 Four treatment plans were developed and delivered to the RPC pelvic phantom.  The three 
coplanar treatment plans included a 4-field box, IMRT, and VMAT.  The one non-coplanar plan was 
a CyberKnife treatment.  The phantom was irradiated three times for each plan to determine the 
ability of the OSLD to measure an equivalent dose to the TLD dose measurements.  Each delivery 
included two TLD in the femoral heads, two TLD in the PTV, and two OSLD in the PTV.  The 
OSLD in the PTV were located adjacent to the TLD, offset from the center of the target by 
approximately the same distance as the TLD.  Only the average doses measured by the TLD and 
53 
 
OSLD in the PTV are reported and compared.  The doses measured by the OSLD were calculated 
using Equation 2.7, and the TLD measured doses were calculated using Equation 2.3.  The ratio of the 
average TLD dose to the average OSLD dose was calculated for each plan.  The ratios of the TLD 
dose to uncorrected OSLD dose for the coplanar treatment plans can be seen below in Table 3.4.  The 
average TLD to OSLD dose ratio and standard deviation for all coplanar deliveries in the table below 
was calculated to be 1.028 ± 0.008.  With the exception of the dose ratio for the treatment delivery ‘4 
field_1’ the OSLD dose differs from the TLD dose by greater than 1%. 
  TLD Dose (cGy) OSLD Dose (cGy) TLD/OSLD 
4 field_1 317.0 313.9 1.010 
4 field_2 317.2 309.2 1.026 
4 field_3 319.3 312.7 1.021 
IMRT_1 297.6 289.7 1.027 
IMRT_2 298.8 289.1 1.034 
IMRT_3 298.0 289.1 1.031 
VMAT_1 320.4 308.3 1.039 
VMAT_2 321.7 311.5 1.033 
VMAT_3 319.4 310.1 1.030 
Table 3.4 TLD to OSLD dose ratios for coplanar treatment plans 
 The angular correction factors determined from the spherical phantom irradiations, shown in 
Table 3.1, were applied to the OSLD calculated doses.  The correction factor for coplanar 18 MV 
treatments of 1.019 was applied to the 4-field measured OSLD doses.  The coplanar 6 MV correction 
factor of 1.040 was applied to the measured doses for the IMRT and VMAT deliveries.  The ratios of 
the TLD dose to angular corrected OSLD dose for the coplanar treatment plans can be seen below in 
Table 3.5.  The average TLD to corrected OSLD dose ratio and standard deviation for the coplanar 
deliveries was calculated to be 0.995 ± 0.006.  For all coplanar treatment deliveries, the corrected 
OSLD dose is within 1% of the dose measured by the TLD, with the exception of ‘IMRT_1’. 
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  TLD Dose (cGy) Corr OSLD Dose (cGy) TLD/Corr OSLD 
4 field_1 317.0 319.9 0.991 
4 field_2 317.2 315.1 1.007 
4 field_3 319.3 318.6 1.002 
IMRT_1 297.6 301.3 0.988 
IMRT_2 298.8 300.7 0.994 
IMRT_3 298.0 300.7 0.991 
VMAT_1 320.4 320.6 0.999 
VMAT_2 321.7 324.0 0.993 
VMAT_3 319.4 322.5 0.990 
Table 3.5 TLD to corrected OSLD dose ratios for coplanar treatment plans 
 The ratio of the TLD measured dose to the OSLD measured dose, without the angular 
correction, for the non-coplanar CyberKnife treatment deliveries can be seen below in Table 3.6.  The 
average TLD to OSLD dose ratio and standard deviation for the non-coplanar treatments was 
calculated to be 1.011 ± 0.003.  Each delivery resulted in an OSLD dose that differed from the TLD 
dose by approximately 1%. 
  TLD Dose (cGy) OSLD Dose (cGy) TLD/OSLD 
CK_1 620.3 612.4 1.013 
CK_2 617.7 613.3 1.007 
CK_3 621.8 613.5 1.013 
Table 3.6 TLD to OSLD dose ratios for CyberKnife treatments 
 From the spherical phantom irradiations, the angular dependence correction factor of 1.038 
for the non-coplanar 6 MV deliveries, specific to CyberKnife treatments, was applied to the OSLD 
doses.  The ratios of the TLD measured dose to the angular corrected OSLD dose for the CyberKnife 
deliveries can be seen below in Table 3.7.  The average TLD to corrected OSLD dose ratio and 
standard deviation was calculated to be 0.974 ± 0.003.  Each CyberKnife treatment delivery resulted 
in a difference between the TLD dose and OSLD dose by greater than 1%. 
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  TLD Dose (cGy) Corr OSLD Dose (cGy) TLD/Corr OSLD 
CK_1 620.3 635.7 0.976 
CK_2 617.7 636.6 0.970 
CK_3 621.8 636.8 0.976 
Table 3.7 TLD to corrected OSLD dose ratios for CyberKnife treatments 
 The response of the OSLD compared to the TLD for the two institution trials was calculated 
by taking the ratio of the TLD dose to the OSLD dose, as done for the previous irradiations.  The 
ratios of the doses for the institution trials, one IMRT delivery and one CyberKnife delivery, can be 
seen below in Table 3.8.  The average TLD to OSLD dose ratio and standard deviation was calculated 
to be 1.040 ± 0.008.  Each trial showed a response difference between the TLD and OSLD of greater 
than 1%. 
 
TLD Dose (cGy) OSLD Dose (cGy) TLD/OSLD 
IMRT 615.6 589.1 1.045 
CyberKnife 675.9 653.5 1.034 
Table 3.8 TLD to OSLD dose ratios for the institution trials 
 Using the angular dependence correction factors employed previously, the corrected OSLD 
doses were calculated.  The OSLD dose for the IMRT trial was multiplied by the angular correction 
factor of 1.040, and the CyberKnife trial OSLD dose was multiplied by the correction factor 1.038.  
The ratios of TLD dose to corrected OSLD dose for the two institution trials can be seen in Table 3.9.  
The average TLD to corrected OSLD dose ratio and standard deviation was calculated to be 1.001 ± 
0.007.  Both the IMRT and CyberKnife institution trials had OSLD angular corrected doses within 
1% of the TLD measured doses. 
  TLD Dose (cGy) Corr OSLD Dose (cGy) TLD/Corr OSLD 
IMRT 615.6 612.1 1.006 
CyberKnife 675.9 679.0 0.995 
Table 3.9 TLD to corrected OSLD dose ratios for the institution trials 
 For each set of irradiations, with the exception of the three CyberKnife irradiations shown in 
Table 3.7, the applied angular correction factors corrected the OSLD dose to within 1% of the 
measured TLD dose, with very low error.  The 6 MV non-coplanar angular correction factor, when 
applied to the OSLD measured dose from the CyberKnife institution trial, adequately corrected the 
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OSLD dose, so it is unclear as to why the correction factor failed to scale the OSLD dose 
appropriately for the other CyberKnife irradiations.  CyberKnife treatments are very non-
homogeneous in nature, so it is possible that even with the TLD and OSLD oriented in the phantom 
to be very close together, there could be large dose differences between the two types of dosimeters, 
making it difficult to compare the angular corrected OSLD dose to the TLD dose.  The films present 
in the phantom at irradiation could be used to determine if large dose differences within the target 
were present, which was not possible for the three CyberKnife treatments in this study as there were 
no films included in the phantom for these irradiations.  Another complication to the CyberKnife dose 
comparison is that the plans between different institutions could vary widely.  The angular delivery of 
the MU from different plans could be very different, and result in differences in dose deposited in the 
OSLD.   
 The outcome of the absolute dose comparisons show that the coplanar 6 MV and 18 MV 
angular correction factors, when applied to the measured OSLD doses, yield equivalent results to the 
TLD measured doses, and can be used for the purpose of credentialing with the RPC’s 
anthropomorphic QA phantoms. 
3.3.2 Dose Profiles 
 The phantom irradiations contained film in the coronal and sagittal planes through the target 
for the three IMRT treatment deliveries, as well as for both institution trials, for the evaluation of the 
agreement between planned and measured doses.  Each film was normalized to the TLD target doses, 
and again for the angular corrected OSLD target doses.  The coronal film is evaluated by taking 
profiles through the PTV in both the lateral and superior-inferior directions.  The sagittal film is 
evaluated by taking profiles through the PTV in the AP and superior-inferior directions.  Selected 
profiles from the second IMRT delivery, ‘IMRT_2’, can be seen in the figures below.  The lateral 
profile taken from the coronal film, normalized to the TLD and corrected OSLD doses can be seen in 
Figures 3.13 and 3.14, respectively.  The AP profile recorded from the sagittal film, normalized to the 
TLD doses can be seen in Figure 3.15, and the profile from the film normalized to the corrected 
OSLD doses can be seen in Figure 3.16.  The drop in measured dose at the center of the AP profile 
from the sagittal film is due to the gap where the edges of the two pieces of the film come together.  
The superior-inferior profiles taken from the sagittal film normalized to the TLD target doses and the 
angular corrected OSLD target doses can be seen in Figures 3.17 and 3.18, respectively.  All other 
profiles for the IMRT and institution trial deliveries can be seen in the Appendix, in Section 5.2.  The 
profiles display the institution reported doses from the TPS, the measured dose from the film 
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normalized to target dosimeter doses, and the point doses from the dosimeters in the target.  These 
dose profiles were not evaluated for quantitative results, but rather as a qualitative analysis of the 
ability of the OSLD to measure equivalent dose to the TLD and provide similar results when 
normalizing film, when an angular dependence correction is made to the OSLD dose. 
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Figure 3.13 Lateral dose profile in coronal plane from IMRT_2 as planned by TPS and measured by 
film normalized to target TLD dose 
 
Figure 3.14 Lateral dose profile in coronal plane from IMRT_2 as planned by TPS and measured by 
film normalized to corrected target OSLD dose 
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Figure 3.15 AP dose profile in sagittal plane from IMRT_2 as planned by TPS and measured by film 
normalized to target TLD dose 
 
Figure 3.16 AP dose profile in sagittal plane from IMRT_2 as planned by TPS and measured by film 
normalized to corrected target OSLD dose 
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Figure 3.17 Superior-inferior dose profile in sagittal plane from IMRT_2 as planned by TPS and 
measured by film normalized to target TLD dose 
 
Figure 3.18 Superior-inferior dose profile in sagittal plane from IMRT_2 as planned by TPS and 
measured by film normalized to corrected target OSLD dose 
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 For each film presented, the films normalized to the angular corrected OSLD target doses 
appear almost identical to the films normalized to the TLD target doses.  While the normalized film 
profiles may not match up well to the institution reported profiles, as seen in the superior-inferior 
profiles from the sagittal films in Figures 3.17 and 3.18, the aim of this study is not to compare the 
OSLD doses or OSLD normalized film to the institution values, but rather to compare the TLD with 
the OSLD.  These results validate that the film can be normalized to the angular corrected OSLD 
target doses for the purposes of credentialing with the RPC’s anthropomorphic QA phantoms. 
3.3.3 Gamma Analysis 
 Another method by which the ability of the OSLD, when a correction for the angular 
dependence is made, to measure equivalent dose to TLD measurements is evaluated was by 
comparing gamma analysis results for film normalized to both TLD doses and OSLD doses, as 
described in Section 2.7.3.  The percent of pixels passing the 7%/4 mm gamma criteria for the three 
IMRT treatment deliveries is shown in Table 3.10.  The pass rates for each film in the phantom 
normalized to the target TLD doses can be seen next to the pass rates for the films normalized to the 
angular corrected OSLD target doses.  The percentage of pixels passing the same gamma criteria for 
the two institution trials can be seen in Table 3.11.  For the purpose of this study, it is not necessary or 
important that the films pass the RPC gamma criteria of greater than 85% of pixels passing, but the 
significance rests in the ability of the OSLD normalized films to pass at the same rate as the TLD 
normalized films.  For the three IMRT deliveries and the two institution trials, the gamma pass rates 
for the films normalized to both the TLD and the corrected OSLD are very close, if not the same.  
The low passing rates for the three IMRT deliveries can be attributed to the low dose delivered to the 
film.  The RPC experience has shown that for a target dose of 3 Gy, the noise properties dominate the 
film, making accurate results difficult to obtain. 
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Film 
TLD Gamma 
Pass Rate 
OSLD Gamma 
Pass Rate 
IMRT_1 Coronal 82% 83% 
  
Sagittal 80% 81% 
IMRT_2 Coronal 88% 88% 
  
Sagittal 85% 84% 
IMRT_3 Coronal 82% 82% 
  
Sagittal 75% 75% 
Table 3.10 Percent of pixels passing gamma analysis for IMRT deliveries in the coronal and sagittal 
films for a criteria of 7%/4 mm for film normalized to TLD dose and corrected OSLD dose 
  
Film 
TLD Gamma 
Pass Rate 
OSLD Gamma 
Pass Rate 
IMRT Coronal 100% 100% 
  
Sagittal 99% 99% 
CyberKnife Coronal 93% 93% 
  
Sagittal 94% 94% 
Table 3.11 Percent of pixels passing gamma analysis for institution trials in the coronal and sagittal 
films for 7%/4 mm criteria for film normalized to TLD dose and corrected OSLD dose 
 The distribution maps, both color scale and binary, for the sagittal and coronal films with 
pixels passing the 7%/4 mm gamma criteria for the irradiation IMRT_2 can be seen below in Figure 
3.19 through Figure 3.26.  The gamma results are shown for both the TLD normalized films and the 
films normalized by the angular corrected OSLD doses.  The gamma analysis results for the 
remaining IMRT deliveries and the institution trials are shown in the Appendix, in Section 5.3. 
 The gamma results for the coronal films from the second IMRT irradiation can be seen 
below, Figure 3.19 shows the coronal film normalized to the TLD target doses and Figure 3.20 shows 
the same film normalized to the corrected OSLD target doses.  The same results, with the binary 
display of pixels passing can be seen below, Figure 3.21 is the result for the TLD normalized film and 
Figure 3.22 is the result for the angular corrected OSLD normalized film.  The areas of pixels passing 
the gamma criteria for both the TLD and OSLD normalized films appear essentially the same. 
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Figure 3.19 IMRT_2 color scale gamma results for coronal film normalized to target TLD dose 
 
Figure 3.20 IMRT_2 color scale gamma results for coronal film normalized to corrected target OSLD 
dose 
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Figure 3.21 IMRT_2 binary gamma results for coronal film normalized to target TLD dose 
 
Figure 3.22 IMRT_2 binary gamma results for coronal film normalized to corrected target OSLD 
dose 
 The gamma results for the sagittal films from the second IMRT irradiation can be seen below, 
Figure 3.23 shows the sagittal film normalized to the TLD doses and Figure 3.24 shows the same film 
normalized to the corrected OSLD doses.  The sagittal film gamma results shown in the binary 
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display, passing pixels appear blue and failing pixels appear green, can be seen below.  Figure 3.25 is 
the result for the TLD normalized film and Figure 3.26 is the result for the angular corrected OSLD 
normalized film.  The areas of pixels passing the gamma criteria for both the TLD and OSLD 
normalized films appear the same, with few variations. 
 
Figure 3.23 IMRT_2 color scale gamma results for sagittal film normalized to target TLD dose 
 
Figure 3.24 IMRT_2 color scale gamma results for sagittal film normalized to corrected target OSLD 
dose 
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Figure 3.25 IMRT_2 binary gamma results for sagittal film normalized to target TLD dose 
 
Figure 3.26 IMRT_2 binary gamma results for sagittal film normalized to corrected target OSLD 
dose 
 The results from the gamma analysis, comparing the pass rates and pixel distributions of the 
TLD normalized films and the corrected OSLD normalized films, demonstrate that the analysis of the 
films when normalized to the angular corrected OSLD target doses yields equivalent results to the 
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TLD normalized films.  The films normalized to the angular corrected OSLD target doses can be used 
for the purpose of credentialing with the RPC’s anthropomorphic QA phantoms. 
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Chapter 4 Conclusions 
4.1 Conclusion 
 This study investigated the angular dependence of the nanoDot OSL dosimeters in the RPC 
pelvic phantom to effectively utilize the OSLD as a replacement for the TLD in the anthropomorphic 
QA phantoms.  The replacement of TLD in the QA phantoms with OSLD would be beneficial to the 
RPC.  The benefits of OSLD include shorter waiting periods post-irradiation, simpler and quicker 
readout procedures, minimal energy dependence, signal is not destroyed when they are read, allowing 
them to be read multiple times, and they are not affected by environmental changes.  As the mini-
phantom portion of the remote audit system has already made the switch to OSLD, the switch from 
TLD to OSLD in the anthropomorphic phantoms would further streamline the remote audit process 
and greatly improve efficiency.   
 OSLD were irradiated within a small, spherical polystyrene phantom to study the angular 
dependence of the dosimeters under the simplest of conditions for both 6 MV and 18 MV photon 
beams.  The results of these irradiations lead to the determination of angular correction factors of 
1.040 and 1.019 for coplanar treatments with beam energies 6 MV and 18 MV, respectively, and a 
correction factor of 1.038 for non-coplanar treatments at 6 MV, specific to CyberKnife treatments.  
Within the experimental uncertainties, the correction factors at 6 MV for the coplanar and non-
coplanar treatments are essentially the same.  
 The irradiations of the RPC pelvic phantom included TLD, OSLD, and film for the IMRT 
and institution trials.  The film was included in the select treatments in order to validate the use of 
OSLD dose, when the angular dependence has been corrected, to normalize the film for obtaining 
dose profiles or performing gamma analysis, and to show that the OSLD normalized film yields the 
same results as film normalized by the TLD doses.  Comparisons of the absolute doses measured by 
the TLD and OSLD, the dose profiles generated by normalized films, and gamma analysis of the 
normalized films were all performed.  The ratio of the doses measured by the TLD to the corrected 
OSLD measured dose was calculated to be 0.995 ± 0.006 for the coplanar treatment deliveries.  The 
ratio of the TLD measured doses to the angular corrected OSLD doses for the non-coplanar treatment 
deliveries was calculated to be 0.974 ± 0.003.  The institution trials served as a method to verify the 
ability of the angular correction factors established from the spherical phantom irradiations to correct 
the OSLD dose to within 1% of the TLD measured dose.  The average ratio of the TLD to corrected 
OSLD dose for the two institution trials was calculated to be 1.001 ± 0.007.  For all irradiations, the 
angular dependence correction factors determined in this study effectively corrected the OSLD 
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measured dose to within 1% of the TLD measured dose, with the exception of the three CyberKnife 
treatment deliveries.   
 Our hypothesis, that the incorporation of OSLD into the RPC phantom will measure on 
average an equivalent dose measurement as compared to the existing TLD measurements within 
±1%, regardless of the angular dependence of the OSLD, was not supported.  Based on the results of 
the study, the OSLD can be effectively used as a replacement for the TLD in the phantoms and 
measure an equivalent dose within 1%, only if the OSLD angular dependence is first corrected. 
 Caution is advised regarding the use of the angular dependence correction factor for the 
OSLD determined in this study for non-coplanar CyberKnife treatment deliveries.  The discrepancies 
between the data from the three CyberKnife treatments delivered at St. Luke’s compared to the 
CyberKnife irradiation for the institution trial were considerable, and the correction factor that 
worked so well when applied to the trial data, did not yield good results when applied to the original 
CyberKnife data.  In addition, the statistical analysis of the OSLD responses from the non-coplanar 6 
MV spherical phantom irradiations showed that averaging the normalized responses might not be the 
appropriate method of establishing the angular dependence correction factor.  A single correction 
factor for the established angular dependence of the OSLD for CyberKnife irradiations may not be 
possible due to the high dose gradients and inherent inhomogeneities of the treatment, and that 
CyberKnife credentialing may need to be performed according to the current method of using TLD as 
the absolute dosimeter.  If a switch from TLD to OSLD is pursued for CyberKnife credentialing using 
the anthropomorphic QA phantoms, further investigation of an appropriate angular dependence 
correction factor must be performed. 
4.2 Future Work 
 The results of this study indicate that the modification of the collection of pelvic phantoms at 
the RPC could begin to include OSLD as a replacement for the TLD for coplanar treatment deliveries 
in both the PTV as well as in the femoral heads.  An investigation of other anthropomorphic QA 
phantoms for which the inclusion of OSLD would be most appropriate, and how the modifications 
would be made could also be done.  With the incorporation of the OSLD into the phantoms, the 
characterization of the energy correction factors for the OSLD in full phantom conditions must be 
completed for additional beam energies, both photon and electron beams. 
 It is also clear from this study that further research regarding the OSLD response for non-
coplanar treatments, such as CyberKnife, and a possible correction factor for the OSLD angular 
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dependence in these situations, must be pursued.  This further study of the dosimeter response for 
non-coplanar CyberKnife treatments might be more feasible when the RPC has credentialed a greater 
number of CyberKnife treatments using the existing method of mailable phantoms with TLD, but also 
including OSLD in the target volume and collecting data on the measured doses.  
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Chapter 5 Appendix 
5.1 TG-21 Worksheets
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5.2 Dose Profiles 
5.2.1 IMRT_1 
 
Figure 5.1 Lateral dose profile in coronal plane from IMRT_1 with film normalized to TLD dose 
 
Figure 5.2 Lateral dose profile in coronal plane from IMRT_1 with film normalized to corrected 
OSLD dose 
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Figure 5.3 AP dose profile in sagittal plane from IMRT_1 with film normalized to TLD dose 
 
Figure 5.4 AP dose profile in sagittal plane from IMRT_1 with film normalized to corrected OSLD 
dose 
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Figure 5.5 Superior-inferior dose profile in sagittal plane from IMRT_1 with film normalized to TLD 
dose 
 
Figure 5.6 Superior-inferior dose profile in sagittal plane from IMRT_1 with film normalized to 
corrected OSLD dose 
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5.2.2 IMRT_3 
 
Figure 5.7 Lateral dose profile in coronal plane from IMRT_3 with film normalized to TLD dose 
 
Figure 5.8 Lateral dose profile in coronal plane from IMRT_3 with film normalized to corrected 
OSLD dose 
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Figure 5.9 AP dose profile in sagittal plane from IMRT_3 with film normalized to TLD dose 
 
Figure 5.10 AP dose profile in sagittal plane from IMRT_3 with film normalized to corrected OSLD 
dose 
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Figure 5.11 Superior-inferior dose profile in sagittal plane from IMRT_3 with film normalized to 
TLD dose 
 
Figure 5.12 Superior-inferior dose profile in sagittal plane from IMRT_3 with film normalized to 
corrected OSLD dose 
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5.2.3 CyberKnife Trial 
 
Figure 5.13 Lateral dose profile in coronal plane from CyberKnife trial with film normalized to TLD 
dose 
 
Figure 5.14 Lateral dose profile in coronal plane from CyberKnife trial with film normalized to 
corrected OSLD dose 
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Figure 5.15 AP dose profile in sagittal plane from CyberKnife trial with film normalized to TLD 
dose 
 
Figure 5.16 AP dose profile in sagittal plane from CyberKnife trial with film normalized to corrected 
OSLD dose 
0
1
2
3
4
5
6
7
8
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7
D
o
se
 
(G
y)
Distance (cm)
TLD Normalized AP Profile - Sagittal Plane
RPC Film Institution Values TLD Left TLD Right
Rectum
AnteriorPosterior
CyberKnife Trial
Prostate
0
1
2
3
4
5
6
7
8
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7
D
o
s
e 
(G
y)
Distance (cm)
Corrected OSLD Normalized AP Profile - Sagittal 
Plane
RPC Film Institution Values TLD Left TLD Right
Rectum
AnteriorPosterior
CyberKnife Trial
Prostate
82 
 
 
Figure 5.17 Superior-inferior dose profile in sagittal plane from CyberKnife trial with film 
normalized to TLD dose 
 
Figure 5.18 Superior-inferior dose profile in sagittal plane from CyberKnife trial with film 
normalized to corrected OSLD dose 
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5.2.4 IMRT Trial 
 
Figure 5.19 Lateral dose profile in coronal plane from IMRT trial with film normalized to TLD dose 
 
Figure 5.20 Lateral dose profile in coronal plane from IMRT trial with film normalized to corrected 
OSLD dose 
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Figure 5.21 AP dose profile in sagittal plane from IMRT trial with film normalized to TLD dose 
 
Figure 5.22 AP dose profile in sagittal plane from IMRT trial with film normalized to corrected 
OSLD dose 
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Figure 5.23 Superior-inferior dose profile in sagittal plane from IMRT trial with film normalized to 
TLD dose 
 
Figure 5.24 Superior-inferior dose profile in sagittal plane from IMRT trial with film normalized to 
corrected OSLD dose 
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5.3 Gamma Analysis 
5.3.1 IMRT_1 Coronal Films 
 
Figure 5.25 IMRT_1 color scale gamma results for coronal film normalized to TLD dose 
 
Figure 5.26 IMRT_1 color scale gamma results for coronal film normalized to corrected OSLD dose 
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Figure 5.27 IMRT_1 binary gamma results for coronal film normalized to TLD dose 
 
 Figure 5.28 IMRT_1 binary gamma results for coronal film normalized to corrected OSLD dose 
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5.3.2 IMRT_1 Sagittal Films 
 
Figure 5.29 IMRT_1 color scale gamma results for sagittal film normalized to TLD dose 
 
Figure 5.30 IMRT_1 color scale gamma results for sagittal film normalized to corrected OSLD dose 
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Figure 5.31 IMRT_1 binary gamma results for sagittal film normalized to TLD dose 
 
Figure 5.32 IMRT_1 binary gamma results for sagittal film normalized to corrected OSLD dose 
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5.3.3 IMRT_3 Coronal Films 
 
Figure 5.33 IMRT_3 color scale gamma results for coronal film normalized to TLD dose 
 
Figure 5.34 IMRT_3 color scale gamma results for coronal film normalized to corrected OSLD dose 
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Figure 5.35 IMRT_3 binary gamma results for coronal film normalized to TLD dose 
 
 Figure 5.36 IMRT_3 binary gamma results for coronal film normalized to corrected OSLD dose 
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5.3.4 IMRT_3 Sagittal Films 
 
Figure 5.37 IMRT_3 color scale gamma results for sagittal film normalized to TLD dose 
 
Figure 5.38 IMRT_3 color scale gamma results for sagittal film normalized to corrected OSLD dose 
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Figure 5.39 IMRT_3 binary gamma results for sagittal film normalized to TLD dose 
 
Figure 5.40 IMRT_3 binary gamma results for sagittal film normalized to corrected OSLD dose 
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5.3.5 CyberKnife Trial Coronal Films 
 
Figure 5.41 CyberKnife trial color scale gamma results for coronal film normalized to TLD dose 
 
Figure 5.42 CyberKnife trial color scale gamma results for coronal film normalized to corrected 
OSLD dose 
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Figure 5.43 CyberKnife trial binary gamma results for coronal film normalized to TLD dose 
 
Figure 5.44 CyberKnife trial binary gamma results for coronal film normalized to corrected OSLD 
dose 
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5.3.6 CyberKnife Trial Sagittal Films 
 
Figure 5.45 CyberKnife trial color scale gamma results for sagittal film normalized to TLD dose 
 
Figure 5.46 CyberKnife trial color scale gamma results for sagittal film normalized to corrected 
OSLD dose 
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Figure 5.47 CyberKnife trial binary gamma results for sagittal film normalized to TLD dose 
 
Figure 5.48 CyberKnife trial binary gamma results for sagittal film normalized to corrected OSLD 
dose 
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5.3.7 IMRT Trial Coronal Films 
 
Figure 5.49 IMRT trial color scale gamma results for coronal film normalized to TLD dose 
 
Figure 5.50 IMRT trial color scale gamma results for coronal film normalized to corrected OSLD 
dose 
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Figure 5.51 IMRT trial binary gamma results for coronal film normalized to TLD dose 
 
Figure 5.52 IMRT trial binary gamma results for coronal film normalized to corrected OSLD dose 
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5.3.8 IMRT Trial Sagittal Films 
 
Figure 5.53 IMRT trial color scale gamma results for sagittal film normalized to TLD dose 
 
Figure 5.54 IMRT trial color scale gamma results for sagittal film normalized to corrected OSLD 
dose 
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Figure 5.55 IMRT trial binary gamma results for sagittal film normalized to TLD dose 
 
Figure 5.56 IMRT trial binary gamma results for sagittal film normalized to corrected OSLD dose 
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